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Abstract 
Designing drugs that are selective is crucial in pharmaceutical research to avoid 
unwanted side effects. To decipher selectivity of drug targets, computational 
approaches that utilize the sequence and structural information of the protein 
binding pockets are frequently exploited. In addition to methods that rely only 
on protein information, quantitative approaches such as proteochemometrics 
(PCM) use the combination of protein and ligand descriptions to derive 
quantitative relationships with binding affinity. PCM aims to explain cross-
interactions between the different proteins and ligands, hence facilitating our 
understanding of selectivity.  
 
The main goal of this dissertation is to develop and apply field-based PCM to 
improve the understanding of relevant molecular interactions through visual 
illustrations. Field-based description that depends on the 3D structural 
information of proteins enhances visual interpretability of PCM models relative 
to the frequently used sequence-based descriptors for proteins. In these field-
based PCM studies, knowledge-based fields that explain polarity and 
lipophilicity of the binding pockets and WaterMap-derived fields that elucidate 
the positions and energetics of water molecules are used together with the 
various 2D / 3D ligand descriptors to investigate the selectivity profiles of 
kinases and serine proteases. 
 
Field-based PCM is first applied to protein kinases, for which designing 
selective inhibitors has always been a challenge, owing to their highly similar 
ATP binding pockets. Our studies show that the method could be successfully 
applied to pinpoint the regions influencing the binding affinity and selectivity 
of kinases. As an extension of the initial studies conducted on a set of 50 
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kinases and 80 inhibitors, field-based PCM was used to build classification 
models on a large dataset (95 kinases and 1572 inhibitors) to distinguish active 
from inactive ligands. The prediction of the bioactivities of external test set 
compounds or kinases with accuracies over 80% (Matthews correlation 
coefficient, MCC: ~0.50) and area under the ROC curve (AUC) above 0.8 
together with the visual inspection of the regions promoting activity 
demonstrates the ability of field-based PCM to generate both predictive and 
visually interpretable models. Further, the application of this method to serine 
proteases provides an overview of the sub-pocket specificities, which is crucial 
for inhibitor design. Additionally, alignment-independent Zernike descriptors 
derived from fields were used in PCM models to study the influence of protein 
superimpositions on field comparisons and subsequent PCM modelling.  
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Tiivistelmä 
 
Lääketutkimuksessa selektiivisten lääkeaineiden suunnittelu on ratkaisevan 
tärkeää haittavaikutusten välttämiseksi. Kohdeselektiivisyyden selvittämiseen 
käytetään usein tietokoneavusteisia menetelmiä, jotka hyödyntävät proteiinien 
sitoutumiskohtien sekvenssi- ja rakennetietoja. Proteiinilähtöisten menetelmien 
lisäksi kvantitatiiviset menetelmät kuten proteokemometria 
(proteochemometrics, PCM) yhdistävät sekä proteiinin että ligandin tietoja 
muodostaessaan kvantitatiivisen suhteen sitoutumisaffiniteettiin. PCM pyrkii 
selittämään eri proteiinien ja ligandien vuorovaikutuksia ja näin auttaa 
ymmärtämään selektiivisyyttä. 
 
Väitöstutkimuksen tavoitteena oli kehittää ja hyödyntää kenttäpohjaista 
proteokemometriaa, joka auttaa ymmärtämään relevantteja molekyylitasoisia 
vuorovaikutuksia visuaalisen esitystavan kautta. Proteiinin kolmiulotteisesta 
rakenteesta riippuva kenttäpohjainen kuvaus helpottaa PCM-mallien tulkintaa, 
etenkin usein käytettyihin sekvenssipohjaisiin kuvauksiin verrattuna. Näissä 
kenttäpohjaisissa PCM-mallinnuksissa käytettiin tietoperustaisia 
sitoutumistaskun polaarisuutta ja lipofiilisyyttä kuvaavia kenttiä ja WaterMap-
ohjelman tuottamia vesimolekyylien sijaintia ja energiaa havainnollistavia 
kenttiä yhdessä lukuisten ligandia kuvaavien 2D- ja 3D-deskriptorien kanssa. 
Malleja sovellettiin kinaasien ja seriiniproteaasien selektiivisyysprofiilien 
tutkimukseen. 
 
Tutkimuksen ensimmäisessä osassa kenttäpohjaista PCM-mallinnusta 
sovellettiin proteiinikinaaseihin, joille selektiivisten inhibiittorien suunnittelu 
on haastavaa samankaltaisten ATP-sitoutumistaskujen takia. Tutkimuksemme 
osoitti menetelmän soveltuvan kinaasien sitoutumisaffiniteettia ja 
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selektiivisyyttä ohjaavien alueiden osoittamiseen. Jatkona 50 kinaasia ja 80 
inhibiittoria käsittäneelle alkuperäiselle tutkimukselle rakensimme 
kenttäpohjaisia PCM-luokittelumalleja suuremmalle joukolle kinaaseja (95) ja 
inhibiittoreita (1572) erotellaksemme aktiiviset ja inaktiiviset ligandit 
toisistaan. Ulkoisen testiyhdiste- tai testikinaasijoukon bioaktiivisuuksien 
ennustaminen yli 80 % tarkkuudella (Matthews korrelaatiokerroin, MCC noin 
0,50) ja ROC-käyrän alle jäävä ala (AUC) yli 0,8 yhdessä aktiivisuutta tukevien 
alueiden visuaalisen tarkastelun kanssa osoittivat kenttäpohjaisen PCM:n 
pystyvän tuottamaan sekä ennustavia että visuaalisesti ymmärrettäviä malleja. 
Tutkimuksen toisessa osassa metodin soveltaminen seriiniproteaaseihin tuotti 
yleisnäkemyksen sitoutumistaskun eri osien spesifisyyksistä, mikä on 
ensiarvoisen tärkeää inhibiittorien suunnittelulle. Lisäksi kentistä johdettuja, 
proteiinien päällekkäinasettelusta riippumattomia Zernike-deskriptoreita 
hyödynnettiin PCM-malleissa arvioidaksemme proteiinien päällekkäinasettelun 
vaikutusta kenttien vertailuun ja sen jälkeiseen PCM-mallinnukseen. 
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Introduction 
Pharmaceutical companies often aim at “magic bullet” drug molecules that act 
exclusively on a singe target, thus minimizing side effects. However, 
complexity of the biological systems poses a major challenge for designing 
selective molecules. Studies conducted to analyse drug-target interaction 
networks have revealed that the majority of the drugs available on the market 
have the potential to bind to multiple targets (Mestres et al., 2008) and are 
likely to induce unwanted side effects (Smith et al., 2006; Peters, 2013). The 
low selectivity profiles of drug molecules highlight the importance of 
understanding the polypharmacological profiles in the initial stages of drug 
design. Proteochemometrics (PCM) (Prusis et al., 2001), a statistical modelling 
approach that aims to quantify the structure-activity relationships by 
considering both protein and ligand features, has been developed to study 
polypharmacology. PCM has been used in this dissertation with the aim of 
elucidating the features that promote selectivity and identifying the potential 
off-targets (proteins not intended as targets) across a protein family. 
 
This dissertation was conducted as a joint collaborative project between the 
Division of Pharmaceutical Chemistry and Technology at the University of 
Helsinki and the Computer-Aided Drug Design group of Orion Pharma. The 
study mainly focuses on the development of field-based PCM approaches and 
their application to understand the selectivity profiles of ligands that bind to 
kinases and serine proteases. The methods developed not only help to predict 
off-targets, but also provide an illustration of the regions in protein binding sites 
and ligands that are likely to influence binding affinity and selectivity.  
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In the initial stages of the project, field-based PCM relying on the fields derived 
from 3D protein structures was established. The concept of using 3D structural 
information in PCM mainly evolved from the application of molecular 
interaction fields to decipher ligand selectivity (Hoppe et al., 2006; Wohlfahrt 
et al., 2009). Field-based PCM was developed to overcome the drawbacks of 
sequence-based PCM. Models that utilize the amino acid sequence descriptor 
information fail to consider the spatial arrangement of amino acids in the 
binding site and have limited visual interpretability.  Nevertheless, the 
orientation or directionality of amino acids is critical for ligand design. 
Therefore, building visually interpretable PCM models that take advantage of 
the highly informative protein field descriptors could benefit the day-to-day 
inhibitor design.  
 
The suitability of employing knowledge-based and WaterMap fields derived 
from protein binding sites in PCM modelling was first tested on kinases, 
resulting in Publications I and II. In Publication I, field-based PCM models 
with a set of 50 kinases and 80 inhibitors were built using the linear Partial 
Least Squares (PLS) regression approach to enable easy interpretation and 
visualization of the kinase and ligand features relevant for selectivity. In 
Publication II, the kinase dataset was expanded to build a global field-based 
PCM model using non-linear machine learning approaches to classify active 
and inactive ligands. Further, the applicability of the field-based methods to 
other protein families was demonstrated by building PCM models with serine 
proteases (Publication III).  
 
Field-based methods are sensitive to shifts in protein superimposition. Building 
PCM models based on the fields calculated from poorly aligned structures 
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could have a significant impact on the model quality. To assess the influence of 
alignment errors in PCM modelling, a systematic comparison was made 
between the models built on protein fields of superimposed proteins and 
alignment-independent Zernike descriptors (Novotni and Klein, 2003)  
(unpublished results). Models based on superimposed protein fields and 
Zernike descriptors have virtually the same performance. For the kinase dataset, 
Matthews correlation coefficient for field-based models is 0.52 and for Zernike 
descriptor based models 0.48. Only preliminary results were obtained at the 
time of writing the thesis.  
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Review of the literature 
The target families used for PCM modelling and overviews of computational 
approaches used for selectivity design are presented in this section.  
 
1 Target families 
1.1 Kinases 
1.1.1 Kinases as enzymes 
Protein kinases are one of the largest families of drug targets, encoded by more 
than 518 genes in humans (Manning et al., 2002). Kinases are enzymes 
involved in phosphorylation, a post-translational modification that catalyses the 
transfer of a phosphate group from adenosine triphosphate (ATP) to the 
substrate proteins (Zuccotto et al., 2010). For a kinase to promote catalysis of 
phosphate transfer, it should remain in the activated state, which can be 
triggered by various signalling events (Johnson, 2007). Following 
phosphorylation, the substrates can alter the recognition properties of enzymes 
through conformational changes. The best example of this phenomenon is the 
sequential activation of kinases in the Mitogen-activated protein kinase 
(MAPK) pathway, where phosphorylation of MAP3K activates MAP2K, which 
in turn triggers MAPK activity (Cargnello and Roux, 2011). Kinases play a key 
role in mediating various cellular, metabolic and signalling pathways via 
phosphorylation (Johnson, 2007; Melnikova and Golden, 2008). Among the 
substrates phosphorylated by kinases are the G protein-coupled receptors 
(GPCRs) that participate in a wide array of signal transduction pathways. The 
phosphorylated GPCRs can in turn initiate other signalling events and cellular 
responses (Tobin, 2008). 
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1.1.2 Kinase families 
All eukaryotic kinases share a catalytic domain that is homologous among the 
kinase subfamilies (Hanks et al., 2013). Apart from the kinase domain, there are 
83 additional domains observed in 258 kinases (Manning et al., 2002). These 
additional domains are unique to certain groups of kinases. They mediate 
various signalling activities and control the phosphorylation states of the 
kinases that act in a network (Manning et al., 2002). Based on phylogenetic 
classification, kinases can be categorized into 11 major groups, which are 
further classified into several families and subfamilies 
(http://kinase.com/wiki/index.php/Kinase_classification; Manning et al., 2002).  
 
1. AGC – Adenine Guanine Cytosine kinase ?  
2. CAMK – Calcium / Calmodulin-dependent protein Kinase ?  
3. CK I – Casein Kinase I ?  
4. CMGC (CDK, MAPK, GSK and CLK families) ?  
5. STE – Serine / Threonine Protein kinase ?  
6. TK – Tyrosine Kinase ?  
7. TKL – Tyrosine Kinase-Like ?  
8. RGC – Receptor Guanylate Cyclases 
9. OPK – Other Protein kinases 
10. PKL – Protein kinase-like / Pseudokinases 
11. Atypical kinases 
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1.1.3 Structural organization of kinases 
 
 
Figure 1. Structural organization of kinase domains. The crystal structure of ABL1 
kinase with the bound inhibitor dasatinib (PDB: 2GQG) is shown here. The kinase 
structure is represented as a cartoon and the ligand is shown in ball and stick style. 
Different colours in the figure correspond to different structural elements. The 
gatekeeper residue, DFG (Asp-Phe-Gly) motif and HRD (His-Arg-Asp) motif are 
shown as thin tubes. 
 
The kinase domain (Figure 1) includes two lobes, namely the N-terminal lobe 
with five ? strands and one ? helix and the C-terminal lobe mainly with ? 
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helices (Huse and Kuriyan, 2002). The ATP molecule binds in a cleft located 
between the two lobes and participates in hydrogen bonding interactions with 
the residues in the hinge region (Zuccotto et al., 2010). A glycine-rich loop 
present in the N-terminal lobe facilitates phosphoryl transfer by interacting with 
ATP. The catalytic loop found in the C-terminal lobe contains the highly 
conserved HRD (His-Arg-Asp) motif that stabilizes the conformation of the 
activation loop (Kornev et al., 2006). The activation loop that is centrally 
located and contains about 20-30 residues controls the activation states of the 
kinases (Huse and Kuriyan, 2002; Kornev et al., 2006). The orientation of the 
DFG (Asp-Phe-Gly) motif present in the activation loop serves as a deciding 
factor for whether the kinases are in active or inactive state (Kornev et al., 
2006). 
 
1.1.4 Active and inactive forms of kinases  
Kinases are known to exist in two different conformations, the DFG-in / active 
and DFG-out / inactive conformation. In the active form, the phenylalanine of 
the DFG motif points away from the ATP binding pocket (Figure 2, left panel) 
and one of the residues, serine, threonine or tyrosine, frequently remains 
phosphorylated in the activation loop (Huse and Kuriyan, 2002; Kornev et al., 
2006). The phosphorylation states of these residues can either be influenced by 
additional domains present in kinases or by autophosphorylation, which occurs 
due to receptor dimerization (Nolen et al., 2004; Johnson, 2009). Nevertheless, 
phosphorylation is not always necessary for kinase activation. There are 
examples of kinases that can be activated without phosphorylation, e.g. CDKs 
that are activated by cyclins (Nolen et al., 2004). In case of inactive 
conformation, the phenylalanine of the DFG motif is oriented towards the ATP 
binding site (Figure 2, right panel), which can sometimes block the ATP 
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binding pocket and direct the ligands towards allosteric pocket (Nolen et al., 
2004; Kornev et al., 2006). 
 
 
Figure 2. Detailed view of the different activation states of kinases. Left panel 
corresponds to the DFG-in conformation of KIT kinase with bound adenosine 
diphosphate (PDB: 1PKG). Right panel represents the DFG-out conformation of KIT 
kinase with the bound inhibitor Imatinib (PDB: 1T46). The X-ray ligands are shown in 
orange and activation loops are shown in magenta in both conformations. 
 
1.1.5 Kinases and associated diseases 
Genetic abnormalities can lead to aberrant activation of kinases (Tsatsanis and 
Spandidos, 2000; Fleuren et al., 2016) that are involved in modulating the cell 
growth and differentiation processes. Their atypical activation can have a 
significant effect on the phosphorylation patterns of the substrates, which might 
lead to uncontrolled proliferation of cells, resulting in cancer (Zhang et al., 
2009; Fleuren et al., 2016). Therefore, kinases are the promising drug targets 
for cancer, alongside heart diseases, diabetes and inflammatory disorders 
(Melnikova and Golden, 2008; Fleuren et al., 2016). 
 
1.1.6 Kinase inhibitors: an overview 
Of the 33 clinically approved kinase inhibitors currently available on the market 
(http://www.brimr.org/PKI/PKIs.htm), many are known to interact with 
multiple kinases and are likely to induce side effects. The vast majority of these 
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inhibitors target the ATP binding site of kinases, whose high similarities often 
pose a major challenge for designing selective inhibitors (Huang et al., 2010). 
Another known issue in kinase inhibitor design is the drug resistance arising 
from gene amplifications and mutations in kinase domains, which frequently 
limits the efficacy of kinase inhibitors (Bikker et al., 2009). A typical example 
for drug resistance is the ineffectiveness of imatinib in targeting BCR-ABL1 
kinase, which has either a mutated gatekeeper residue (T315I), resulting in 
unfavourable interactions, or includes multiple copies of the gene, leading to 
reactivation of signalling pathways (Gorre et al., 2001; Daub et al., 2004; 
Barouch-Bentov, 2012). 
 
1.1.7 Selectivity of kinase inhibitors 
Generally, type I inhibitors compete with ATP and bind to rigid active 
conformations (Liu and Gray, 2006; Muller et al., 2015). These inhibitors 
mainly interact with the residues in hinge region by forming hydrogen bonds 
(Zuccotto et al., 2010). The hinge interactions are well conserved among the 
kinase families. Therefore, the gatekeeper residue located close to the hinge 
region acts as a determinant for the selectivity of type I inhibitors by 
influencing the size/accessibility of the hydrophobic back pockets (Zuccotto et 
al., 2010, Muller et al., 2015). The presence of smaller and medium gatekeeper 
residues such as Leu, Val, Thr and Met offers more room in the back cavity, 
thereby promoting the efficacy and selectivity of kinase inhibitors. On the other 
hand, bulky residues such as Phe and Tyr often contribute to steric hindrance 
and restrict inhibitor binding (Zuccotto et al., 2010). An example of a highly 
potent inhibitor, where the small size of the gatekeeper residue is exploited for 
selectivity, is skepinone-L, which targets the p38?/? MAPK kinase (Koeberle 
et al., 2011). 
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Type II inhibitors bind to inactive conformations that have dynamic and 
extended binding pockets  (Liu and Gray, 2006; Muller et al., 2015). These 
inhibitors also participate in hinge interactions that mimic ATP. Additionally, 
they interact with the hydrophobic back pockets, enhancing their selectivity 
(Muller et al., 2015). BCR-ABL inhibitors imatinib and nilotinib serve as 
examples for achieving selectivity through interactions with the hydrophobic 
back pocket (Barouch-Bentov, 2012; Muller et al., 2015).  
 
Non-ATP competitive inhibitors known as type III inhibitors bind to the 
allosteric pocket that is adjacent to the hydrophobic pocket in DFG-out kinases 
(Muller et al., 2015). Allosteric pockets are not well conserved across kinases 
(Treiber and Shah, 2013) and this contributes to the high selectivity of type III 
inhibitors. An example of an allosteric inhibitor that adopts type III binding 
mode is trametinib, which targets MEK1 and MEK2 kinases (Zhao et al., 
2014). 
  
Recently, the cavity between the folded p-loop / glycine-rich loop and helix ?C 
has been targeted for designing the selective inhibitor SCH772984 against 
ERK1/2 kinase. This selectivity strategy could be exploited for kinases that 
have folded p-loop conformations (Muller et al., 2015). 
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1.2 Serine proteases 
1.2.1 Proteases as enzymes 
More than 550 genes in humans encode proteases (Puente et al., 2003; Cera et 
al., 2009). Proteases are enzymes that catalyse the cleavage of peptide bonds of 
their substrates (Cera et al., 2009). Information concerning all proteases and 
their probable cleavage sites is included in the MEROPS database 
(http://merops.sanger.ac.uk), a comprehensive resource (Rawlings, 2016). 
Proteases have a pivotal role in regulating various physiological processes 
including cell-cycle regulation, digestion, blood coagulation, wound healing 
and immune response (Hedstrom et al., 2002; Cera et al., 2009). They also act 
as key regulators of signalling pathways, as proteolysis (digestion of peptides to 
amino acids) can modulate the activities of many kinases and transcription 
factors (Ehrmann and Clausen, 2004).  
 
1.2.2 Protease families 
Proteases are broadly classified into 7 families, depending on the catalytic 
residues or metal ions involved in protein degradation: threonine proteases, 
aspartic proteases, serine proteases, cysteine proteases, metalloproteases, 
glutamic acid proteases and asparagine peptide lyases (Oda, 2012). Nearly one-
third of the human proteases belong to the serine protease family (Puente et al., 
2003; Cera et al., 2009). Serine proteases can further be classified into several 
subfamilies based on their substrate specificities. Trypsin-like and 
chymotrypsin-like proteases that have roles in digestion, thrombin-like 
proteases that are involved in blood coagulation and elastase-like proteases that 
trigger immune response comprise the serine proteases found in eukaryotes. 
Another class of serine proteases known as subtilisin-like proteases is mainly 
found in prokaryotes and it differs from other subfamilies based on the 
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arrangement of catalytic residues in protein scaffolds (?/? in subtilisin and ?/? 
in other subfamilies) (Siezen and Leunissen, 1997). Only the eukaryotic serine 
proteases are discussed in detail in the following sections. 
 
1.2.3 Structural organization of serine proteases 
Serine proteases have two six-stranded ? barrels with the active site enclosed 
between the two (Hedstrom et al., 2002) (Figure 3). A catalytic triad formed by 
aspartate, serine and histidine residues in the active site acts as a charge relay 
system (Hedstrom et al., 2002; Cera et al., 2009). These catalytic triads form a 
part of the extensive intramolecular hydrogen-bonding network and regulate the 
activities of serine proteases (Hedstrom et al., 2002). Another component linked 
to the catalytic triad is the oxyanion hole, a pocket formed between the 
positively charged backbone NH groups of Gly193 and Ser195 residues in the 
active site and the negatively charged carbonyl groups of substrate peptides. 
The oxyanion hole is involved in the stabilization of transition state 
intermediates formed during peptide hydrolysis (Hedstrom et al., 2002). 
Further, the active site is divided into sub-pockets characterized by specific 
amino acid residues that cleave different regions of the substrate peptide 
(Figure 4). 
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Figure 3. Structural organization of serine proteases. The crystal structure of 
coagulation factor Xa with the bound inhibitor ZK-807834 (PDB: 1FJS) is shown here. 
The protease structure is represented as a cartoon and the ligand is shown in ball and 
stick style. The catalytic triad Asp102-His57-Ser195 is shown in orange as thin tubes. 
S1, S2 and S4 correspond to the different sub-pockets. The residues in S1 (Asp189), 
S2 (Tyr60, Gln61) and S4 (Tyr99, Phe174, Trp215) are shown as thin tubes, 
highlighted in green, blue and magenta, respectively. 
 
1.2.4 Activation of serine proteases 
Serine proteases or in general proteases exist as inactive precursors termed 
‘zymogens’ to avoid unwanted protein degradation. These zymogens have a 
distorted active site and are converted into active enzymes upon initiation of 
peptide-bond cleavage in the N-terminus region (Neurath et al., 1967; Khan and 
James, 1998). Zymogen activation can also be influenced by a drop in pH 
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levels, an autocatalytic mechanism (Khan and James, 1998). Examples of 
zymogens that are later converted to active serine proteases include 
chymotrypsinogen, trypsinogen and proelastase. Upon activation, they are 
converted into chymotrypsin, trypsin and elastase, respectively (Khan and 
James, 1998). 
 
1.2.5 Sub-pocket specificity of serine proteases 
The interactions occurring at the protein-protein interface between substrates 
and enzymes act as the determinants of sub-pocket specificity. The active sites 
of the proteases that bind to the substrate and catalyse the proteolysis reaction 
are usually represented as Sn…S4-S3-S2-S1?S1’-S2’-S3’-S4’…. Sn’ from N 
terminus to C terminus (Schechter, 2012). The corresponding substrate peptide 
residues on which these proteases act are denoted as Pn…P4-P3-P2-P1?P1’-
P2’-P3’-P4’…. Pn’. The cleavage occurs in the region between prime and non-
prime sites (P1’?P1) (Figure 4). The cleavage sites are unique for specific 
proteases.  
Figure 4. Illustration of sub-pockets and peptide sites of proteases. Reproduced in part 
by permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery (Turk, 
B. Targeting Proteases: Successes, Failures and Future Prospects. Nat. Rev. Drug 
Discov. 2006, 5 (9), 785–799.), copyright (2006). 
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Generally, analysis of sub-pocket specificities in proteases is focused on S1/P1 
interactions (Hedstrom et al., 2002). Considering the S1 specificities of serine 
protease subfamilies, the trypsin-like and thrombin-like proteases have a 
negatively charged Asp, which prefers substrates with positively charged Lys / 
Arg at P1. On the other hand, the hydrophobic Phe and Val residues of 
chymotrypsin-like and elastase-like proteases have a preference for substrates 
that contain aromatic or small aliphatic residues at P1. S1-S4 sub-pocket 
specificities of the four serine protease subfamilies are shown in Figure 5. 
 
 
Figure 5. Sub-pocket specificities of serine protease families. The ligands are shown in 
green with the ball and stick style. Key residues in the different sub pockets S1 (green), 
S2 (blue) and S4 (magenta) are shown as thin tubes. (a) Trypsin-like (PDB: 2XBW) 
(b) Thrombin-like (PDB: 1QUR) (c) Chymotrypsin-like (PDB: 3N7O) (d) Elastase-
like (PDB: 5A8X) 
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1.2.6 Proteases and associated diseases 
Diminished proteolysis or excessive proteolysis resulting from genetic 
irregularities affects many signalling pathways that have predominant roles in 
causing cancer, inflammation, cardiovascular diseases and viral infection (Drag 
and Salvesan, 2010). The role of proteases in regulating a multitude of 
biological processes makes them promising drug targets. 
 
1.2.7 Protease inhibitors: an overview 
Thirty-two protease inhibitors targeting various protease classes, such as 
metallo (14), aspartic (8), serine (9) and threonine (1), have been approved so 
far to treat hypertension, thrombosis, respiratory diseases, pancreatitis and 
cancer (Turk, 2006). Protease inhibitors can be small molecules (e.g. 
Angiotensin Converting Enzyme (ACE) inhibitor, captopril) or peptides (e.g. 
Factor X inhibitor, bivalirudin) or peptidomimetics (e.g. HIV protease inhibitor, 
saquinavir). A majority of the protease inhibitors currently available on the 
market target ACE, which regulates blood pressure (Turk, 2006). 
 
Based on their mechanism of action, peptidic inhibitors targeting serine 
proteases can be grouped into three categories, namely canonical, non-
canonical and serpins.  
Canonical inhibitors are reversible protein inhibitors whose binding is 
influenced by the presence of a protease-binding loop that remains 
complementary to the active site (Krowarsch et al., 2003). Their interactions 
mimic enzyme-substrate complexes (Turk, 2006). Hirustasin, which inhibits 
trypsin, chymotrypsin and kallikrein, is an example of a canonical inhibitor.  
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Non-canonical inhibitors are peptides that bind through their N-terminus to the 
active site, forming a strong parallel ? sheet, which is further strengthened by 
additional interactions with the regions outside the active site (Krowarsch et al., 
2003). Hirudin, a natural peptide inhibitor, interacts with the thrombin active 
site in a similar fashion. 
 
Serpins (serine proteinase inhibitors) are globular proteins that act as natural 
irreversible inhibitors of serine proteases (Gettins, 2002). Serpins tend to adopt 
multiple conformations and modulate the activity of serine proteases through a 
complete blockage of the active sites (Janciauskiene, 2001). Typical examples 
of serpin inhibitors include Alpha-1 antitrypsin, which acts on neutrophil 
elastases, and antithrombin, which regulates various coagulation factors. 
Mutations in serpins can affect their inhibitory properties, leading to several 
disease states, including inflammation, bleeding disorders and 
neurodegenerative diseases (Janciauskiene, 2001). 
 
Besides peptidic inhibitors, there are many competitive small molecule 
inhibitors. Some synthetic covalent inhibitors such as halomethyl ketones and 
?-lactams bind irreversibly to serine proteases (Sanderson, 1999; Powers et al., 
2002). The irreversible inhibitors are usually not favoured owing to selectivity 
issues arising from their tendency to block many proteases (Turk, 2006). 
Therefore, designing reversible inhibitors that resemble the transition state 
intermediates of substrate hydrolysis is an ideal strategy in the protease field 
(Turk, 2006; Drag and Salvesan, 2010). Examples of reversible inhibitors 
include non-covalent thrombin inhibitors such as argatroban and napsagatran 
(Sanderson, 1999). 
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Selective targeting of proteases can be achieved by designing inhibitors that 
bind non-competitively through exosite and allosteric interactions. Exosite 
inhibitors have direct effects on the active site and influence the catalytic rates 
by binding to secondary sites that remain far from the active site (Turk, 2006; 
Drag and Salvesan, 2010). The thrombin inhibitor desirudin, which binds to the 
fibrinogen-binding site, is an example of an exosite inhibitor (Warkentin, 
2004). Allosteric inhibitors have indirect effects on substrate recognition by 
inducing conformational changes in the enzymes and are highly selective. The 
designed ankyrin repeat proteins (motifs with 33 residues) that target caspase-2 
protease serve as an example of allosteric inhibition (Drag and Salvesan, 2010). 
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2 Selectivity of drug targets 
The term ‘selectivity’ refers to the potential of a ligand to bind to a specific 
drug target or affect a particular cell population (Mecher et al., 2005). A drug 
that hits many targets and pathways besides the desired ones can have harmful 
side effects. As of September 2015, altogether 270 drugs have been withdrawn 
from the market due to adverse effects resulting from their binding to off-
targets (http://cheminfo.charite.de/withdrawn). Non-steroidal anti-inflammatory 
drugs like rofecoxib and valdecoxib, which have the potential to increase the 
risk of heart attack and stroke, serve as typical examples of drug withdrawals 
that are initiated for safety reasons (Qureshi et al., 2011). It is also very 
common that candidate drugs have to be pulled from clinical trials because of 
adverse drug reactions (Kola and Landis, 2004; Peters, 2013). Since drug 
development is expensive and time-consuming, screening for potential off-
targets and analysing the selectivity profiles of ligands in the early stages of 
drug design are likely to reduce failure rates at a later point (Peters, 2013).   
 
Nevertheless, selectivity should not be gained at the expense of efficacy 
(Mencher and Wang, 2005). It is highly probable that the effectiveness of a 
drug might be reduced by directing it to a single target. Disease states are often 
influenced by multiple targets or in many cases the involvement of biological 
pathways rather than individual targets (Mencher and Wang, 2005; Mestres et 
al., 2008). Therefore, considering selectivity in a broader sense by designing 
promiscuous ligands that have targeted polypharmacology by acting on targets 
associated with specific biochemical pathways would help to establish a 
balance between efficacy and side effects induced by non-specific binding 
(Peters, 2013). An example for targeted polypharmacology is the kinase 
inhibitor sorafenib, which is highly effective in controlling tumor progression 
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and angiogenesis by acting on vascular endothelial growth factor receptor 
(VEGFR) and platelet-derived growth factor receptor (PDGFR). Apart from 
being efficacious, its limited side effects make sorafenib a promising inhibitor 
for treating renal cell and hepatocellular carcinomas (Adnane et al., 2005). 
 
2.1 Computational approaches to address selectivity 
Pharmaceutical companies usually conduct safety screening against a panel of 
targets to test for potential off-target effects (Peters, 2013). Despite the 
availability of a multitude of experimental approaches (Graczyk, 2007; 
Karaman et al., 2008; Cheng et al., 2010), conducting an exhaustive screening 
is often not possible. Computational approaches that consider the binding 
characteristics, such as shape, electrostatics, flexibility, hydration and allostery 
are frequently exploited to understand selectivity across protein families, taking 
advantage of the target’s structural information (Huggins et al., 2012). 
Commonly used computational methods for selectivity design are described in 
the following section, with a specific focus on examples related to kinases and 
proteases. 
 
2.1.1 Shape complementarity 
Designing a ligand whose shape remains complementary to the binding pocket 
helps to gain selectivity by optimizing the interactions with the binding site 
residues (Huggins et al., 2012). Shape complementarity can be analysed 
through ligand-based approaches such as Phase Shape (Sastry et al., 2011). 
Examples of achieving selectivity through shape complementarity include the 
design of ROCKI (Rho-associated protein kinase) inhibitors, whose ATP 
binding site shape is influenced by the unique arrangement of five key residues 
not found in other kinases (Breitenlechner et al., 2003), and the development of 
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HIV protease inhibitors, in which the mutant I84V affects the binding site 
shape, and hence, the affinity of the inhibitors (Kovalevsky et al., 2006).  
 
2.1.2 Charge complementarity 
Charge complementarity is a key concept in molecular recognition. Charged 
ligands form salt bridges (combination of electrostatic and hydrogen bonding 
interactions), which enhance their selectivity profiles against lipophilic ligands 
(Huggins et al., 2012). Variations in charges across the binding pockets can be 
analysed through the calculation of molecular electrostatic potentials with the 
help of software packages such as Adaptive Poisson Boltzmann Solver (Baker 
et al., 2001). Differences in the electrostatics of the S1 sub-pocket of factor Xa 
(Gln192) and thrombin (Glu192) have been exploited to design a selective 
inhibitor DX-9065, which is ~20 times more potent on factor Xa than thrombin 
(Pinto et al., 2010). 
 
2.1.3 Conformational flexibility 
Accounting for conformational flexibilities through molecular dynamics 
simulations distinguishes the desired target from an off-target, thereby 
improving selectivity (Huggins et al., 2012). This is true for kinases that switch 
between DFG-in and DFG-out conformations based on the movements of the 
activation loop. The tendency to adopt the DFG-out conformations is not 
observed in many kinases, which provides an opportunity for designing 
inhibitors that selectively target DFG-out states (Huggins et al., 2012). Typical 
examples include imatinib and BIRB796, which inhibit the DFG-out states of 
ABL and p38 MAP kinase, respectively. 
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2.1.4 Water molecules in the binding site 
Position and energetics of water molecules in the binding site, analysed through 
approaches such as WaterMap, have been shown to influence selectivity 
profiles of drug molecules (Abet et al., 2008; Robinson et al., 2010; Beuming et 
al., 2012). A ligand that binds by displacing unfavourable water molecules in 
the target can have many fold higher affinity than an off-target (Huggins et al., 
2012). Analysing the thermodynamic properties of water molecules in the 
factor Xa binding site revealed that displacing the entropically structured water 
molecules in the S4 sub-pocket enhanced ligand binding by contributing to 
energetically favourable interactions with the hydrophobic residues of the S4 
sub-pocket (Abel et al., 2008). In another study, the presence of high-energy 
hydration sites displaced during ligand binding in Src kinase has been 
suggested to increase the binding affinity by 15-fold relative to GSK-3?, which 
lacked this hydration site (Robinson et al., 2010). 
 
2.1.5 Allosteric binding 
Targeting binding sites other than the primary active sites could enhance 
selectivity with respect to off-targets (Huggins et al., 2012). Although 
computational approaches such as molecular dynamics can support the 
identification of allosteric sites, experimental confirmation is required in most 
cases. Kinase inhibitors that bind to the allosteric pocket of DFG-out 
conformations have been shown to be selective, compared with the DFG-in 
inhibitors targeting ATP binding sites (Zuccotto et al., 2010; Treiber and Shah, 
2013). 
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2.2 Systematic comparison of protein binding sites: a strategy to elucidate 
ligand selectivity 
Comparing proteins based on binding site properties extracted from sequence 
and structure information has been shown to be valuable for understanding the 
selectivity of ligands. Selected studies focusing on the comparison of binding 
sites in kinases and serine proteases are presented here. 
 
2.2.1 Kinases 
? Identification of energetically favourable binding site residues that influence 
a specific kinase-ligand interaction generates a binding site signature. 
Subsequent mapping of these signatures to the multiple sequence alignment 
of all protein kinases could recognize potential off-targets (Sheinerman et 
al., 2005). 
? Hierarchical clustering of 75 kinases utilizing knowledge-based interaction 
fields derived from polar and lipophilic probes grouped the kinases 
distinctly based on their ligand binding modes and different conformations 
of the activation loops. The possibility to compute similarity and difference 
fields provides a way to visualize the regions that can be exploited for 
selectivity design (Hoppe et al., 2006). 
? FLAP (Fingerprints for Ligands and Proteins) approach allows exploration 
of the protein-ligand interaction space by defining 4-point pharmacophoric 
fingerprints based on molecular interaction fields for proteins and the 
features complementary to the binding site for ligands. FLAP analysis that 
accounts for shape complementarity and flexibility when applied to kinases 
could distinguish the similarities and differences among binding sites and 
contribute to selective inhibitor design (Baroni et al., 2007). 
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? Binding site similarity analysis based on a geometric hash approach, which 
accounts for atom-atom similarity, and CavBase, which characterizes the 
properties of protein binding sites, explained probable cross-relationships 
among kinase subfamilies (Kuhn et al., 2007; Kinnings and Jackson, 2009).  
? Pharmacophoric fingerprints extracted from C? atoms in the binding cavity 
classified the ATP binding sites of 522 kinases with an AUC (Area Under 
the ROC Curve; For details, see Methods) of 0.89. The distinct 
classifications of kinase sub-groups generated by this alignment-free 
approach could provide a way to analyse the ligand binding preferences of 
various kinase families (Figure 6) (Weill and Rognan, 2010).  
? Alignment-independent Zernike descriptors computed from DrugScore 
potential fields enabled identification of distant kinases that are likely to be 
hit by similar ligands, thereby providing a way to predict off-targets and 
hence selectivity (Nisius and Gohlke, 2012). 
? Exploration of the key binding site interactions from knowledge-rich 
databases like KLIFS (Kinase-Ligand Interaction Fingerprints) could 
provide insight into the affinity and selectivity promoting regions of kinase 
families and subfamilies (http://klifs.vu-compmedchem.nl; Van Linden et 
al., 2014). 
? Knowledge on differences in ATP binding pockets computed from multiple 
target and off-target structures, using a grid-based pocket detection 
approach, enables visualization of kinase sub-pockets relevant for designing 
selective inhibitors (Volkamer et al., 2016). 
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Figure 6. ATP binding sites of multiple PDB structures representing 4 kinase 
subtypes, clustered based on the pharmacophoric fingerprints of binding cavities. 
Figure reproduced with permission from (Weill, N.; Rognan, D. Alignment-Free Ultra-
High-Throughput Comparison of Druggable Protein-Ligand Binding Sites. J. Chem. 
Inf. Model. 2010, 50 (1), 123–135). Copyright (2010) American Chemical Society. 
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2.2.2 Serine proteases 
? Clustering the water sites found in the crystal structures of thrombin and 
trypsin revealed the presence of 22 conserved water sites in thrombin that 
contribute to substrate specificity and could be readily exploited for 
thrombin inhibitor design (Sanschagrin et al., 1998). 
? GRID molecular interaction fields of 3D protein structures computed with 
ten different probes and subsequent principal component analysis identified 
the selectivity promoting regions of factor Xa, trypsin and thrombin 
(Kastenholz et al., 2000). 
? Hierarchical clustering of knowledge-based interaction fields derived with 
polar and lipophilic probes highlighted differences in ligand binding 
specificities for trypsin, thrombin and factor Xa (Hoppe et al., 2005).  
? Cluster analysis of the serine protease families based on the properties of 
binding cavities detected by CavBase explained cross-reactivity (Figure 7) 
(Glinca and Klebe, 2013).    
? C? distance calculations of amino acid residues and subsequent multivariate 
analysis identified the deviations in distances of sub-pocket residues 
between the coagulation factors (II, VII, IX, X and XI) (Uzelac et al., 2015).   
? Ensemble clustering of the propagated motifs that lie in close proximity to 
the binding cavity captured the conformational flexibilities of binding sites 
and classified the serine protease families correctly based on their ligand 
binding preferences (Guo and Chen, 2015). 
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Figure 7. Heatmap showing the clusters of serine proteases generated based on the 
properties of binding cavities. Deep blue and deep red colours correspond to maximum 
similarity and dissimilarity, respectively. Black lines in the heatmap separate the 
different clusters. Figure reproduced in part with permission from (Glinca, S.; Klebe, 
G. Cavities Tell More than Sequences: Exploring Functional Relationships of 
Proteases via Binding Pockets. J. Chem. Inf. Model. 2013, 53 (8), 2082–2092). 
Copyright (2013) American Chemical Society. 
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3 Deciphering ligand selectivity through predictive modelling 
Apart from the computational approaches presented above, ligand selectivity 
can also be investigated through Structure Activity Relationship (SAR) 
analysis. The concept of SAR first evolved from the analysis of the relation 
between chemical composition of ammonium salts and their physiological 
action (Brown and Fraser, 1868). An attempt to estimate this relationship 
quantitatively was introduced by Hansch and Fujita in 1964 (Hansch and Fujita, 
1964). Quantitative structure-activity relationship (QSAR) and quantitative 
structure-property relationship (QSPR) are the statistical methods commonly 
employed in drug discovery to elucidate relationships between chemical 
structures and biological activities / physicochemical properties.  
 
3.1 QSAR: an overview 
QSAR models can highlight ligand features that have the potential to modulate 
the ligands’ activities at drug targets, hence providing a way to propose suitable 
chemical modifications relevant for enhancing the efficacy of the ligand. Since 
its inception in 1964, there has been a growing trend for applying QSAR 
modelling in various fields of science. A simple search in PubMed with the 
term “QSAR” results in 14587 hits with more than 500 publications in 2016, 
revealing the popularity of these methods. QSAR models should be validated 
based on a set of principles published by the Organization for Economic Co-
operation and Development (OECD), with a specific focus on robustness, 
applicability domain and mechanistic interpretation (http:// www.oecd.org). 
Apart from their applications in drug discovery to predict binding affinities and 
toxicities, QSAR techniques are also used in other fields such as environmental 
research, chemical mixtures modelling and nanomedicine (for review, see 
Cherkasov et al., 2014).  
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3.1.1 Classical versus non-classical QSAR 
QSAR techniques fall into two categories, namely classical and non-classical 
QSAR depending on the compound series, descriptors and machine learning 
approaches used for modelling (Table 1) (Fujita and Winkler, 2016). 
 
Table 1. Differences between classical QSAR and non-classical QSAR models 
(adapted from Fujita and Winkler, 2016). 
 
 Classical QSAR Non-classical QSAR 
Type of compounds Congeneric series Large and diverse datasets 
Descriptors Empirical descriptors like 
Hammett substituent 
parameters and log P that 
reflect the compound’s 
electrostatic, hydrophobic 
and steric properties 
Non-empirical descriptors 
that cover a wide range of 
properties including 
physicochemical 
properties, molecular 
connectivity and 
stereochemistry 
Machine learning approach Simple linear regression 
techniques like PLS 
Both linear and non-linear 
techniques (PLS, RF, 
SVM, etc.) 
Applicability domain  Small; local models Reliable predictions for a 
large set of new 
compounds; global models 
Interpretation Easy to interpret and gain 
clear insights into relevant 
molecular features 
Limited interpretability 
due to multiple modes of 
action resulting from 
heterogeneous datasets 
PLS – Partial Least Squares Regression; RF-Random Forests; SVM-Support Vector 
Machines 
 30 
3.1.2 QSAR modelling 
QSAR modelling involves a series of steps: data collection, data curation, 
descriptor calculation, model building and model validation. A typical QSAR 
modelling workflow is presented in Figure 8 (Golbraikh et al., 2012).  
 
 
Figure 8. Predictive QSAR modeling workflow. Figure reproduced by permission 
from John Wiley & Sons, Inc.: Tropsha, A. Best Practices for QSAR Model 
Development, Validation, and Exploitation. Mol. Inform. 2010, 29 (6–7), 476–488., 
copyright (2010). 
 
Data collection 
The most common resources for extracting structural and activity data suitable 
for QSAR modelling are public databases like ChEMBL (Bento et al., 2014), 
ZINC (Irwin et al., 2012) and PubChem (Kim et al., 2016). Also, commercial 
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databases such as WOMBAT and Merck Index are used (for review, see Oprea 
and Tropsha, 2006).  
 
Data curation 
Following data collection, data need to be curated to avoid errors resulting from 
incorrect chemical structures. Adopting a curation protocol that involves 
removal of inorganic compounds and salts, removal of duplicates and 
standardization of chemical structures would allow generation of reliable 
chemical structures ideal for descriptor calculations (Fourches et al., 2010). In 
addition to the chemical structures, the quality of biological data also influences 
QSAR modelling (Williams and Ekins, 2011). Care should be taken when 
utilizing the data generated by experiments conducted under similar assay 
conditions.   
 
Descriptor calculations 
QSAR models can be derived from 1D, 2D or 3D descriptors that differ by the 
level of information encoded (Damale et al., 2014). Seldom, QSAR modelling 
is also extended to 4D or more, with the inclusion of advanced descriptors that 
takes into account e.g. ligand and receptor flexibility (Kuz’min et al., 2005). A 
detailed account of the descriptors used in QSAR modelling is provided in 
Table 2. 
 
 
Model building 
QSAR models are generally built by employing supervised machine learning 
algorithms (Wikberg et al., 2011). Supervised approaches allow the model to 
learn from the training set that includes both input data and output variables. 
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The knowledge acquired is then used to predict an external set. Supervised 
machine learning approaches can be further classified into regression and 
classification techniques based on the output variables involved, either real 
values or class labels (Wikberg et al., 2011). Examples of supervised machine 
learning algorithms include linear regression, random forests, support vector 
machines and artificial neural networks. The choice of the machine learning 
algorithm to be used for QSAR modelling depends on many factors such as the 
dataset, model training time, predictive performance on external test sets and 
ease of interpretation (Sorich et al., 2003; Louis et al., 2010; Wikberg et al., 
2011; Varnek and Baskin, 2012).  
 
Model validation 
QSAR models can be evaluated by internal cross-validation involving repeated 
exclusion of subsets of compounds from model training and using them for 
predictions, external prediction of compounds not used for training and Y-
scrambling, which involves randomization of response variables (Grammatica 
et al., 2007; Tropsha, 2010; Golbraikh et al., 2012). Correlation between the 
observed and predicted variables (R2), predictions from cross-validation (Q2) 
and errors from cross-validation / external prediction (RMSEP) are some of the 
measures commonly used to assess prediction performances of QSAR models 
(For details on performance measures, see Methods). 
 Machine learning algorithms used for model building and model validation 
used in this thesis are explained in detail in the Methods section. 
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3.1.3 Comparative molecular field analysis in medicinal chemistry 
Comparative molecular field analysis (CoMFA) (Cramer et al., 1988), a 3D 
QSAR technique that relies on a template with the native binding mode has 
long been used in medicinal chemistry for its ability to visually illustrate the 
features of ligands that affect biological activity (Verma et al., 2010). CoMFA 
models are built based on a grid defined around the ligands that are 
superimposed on the template. The interaction energies calculated from steric 
and electrostatic fields are assigned to the grid points and are later used as 
descriptors to study their correlation with biological activities using Partial 
Least Squares (PLS) regression approach. The output from PLS models is then 
used to generate contour maps to gain visual understanding (Cramer et al., 
1988; Zhang et al., 2011). 
 
3.1.4 QSAR and selectivity 
Assessing selectivity through QSAR has often been shown to be tedious, as it 
involves generation and comparison of multiple QSAR models. Studies on 
serine proteases demonstrated that multiple CoMFA models had to be 
generated for different classes of serine proteases (factor Xa, thrombin, tissue 
plasminogen activator, trypsin and plasmin) to understand the selectivity of a 
series of indole/benzimidazole-5-carboxamidines (Bhongade et al., 2005). 
 
An alternative approach to circumvent the limitations of generating multiple 
QSAR models for selectivity analysis is comparative binding energy analysis 
(COMBINE). In COMBINE, the interaction energies calculated from ligand-
receptor complexes are used to predict bioactivities (Ortiz et al., 1995). 
COMBINE analysis of ligands bound to several structurally related receptors 
could guide selectivity design. Studies on a series of 3-amidinophenylalanines 
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bound to various serine proteases showed that COMBINE could be successfully 
used to analyse the sub-pocket specificities of thrombin, trypsin and factor Xa 
(Murcia et al., 2006). 
 
3.2 Proteochemometrics 
Although QSAR modelling is frequently used to understand SAR, its 
dependency on ligand descriptors limits its usefulness in selectivity-related 
studies. Despite the availability of approaches like COMBINE for selectivity 
analysis, the need to generate ligand-receptor complexes through docking is a 
drawback. As the quality of the docked poses can often be questionable, using 
them to calculate interaction energies poses a major challenge for generating 
reliable QSAR models based on COMBINE. To deal with all of these 
limitations, Peteris and his co-workers developed proteochemometrics (Prusis 
et al., 2001), a method that accounts for selectivity by combining both protein 
and ligand description with experimentally measured data. In 
proteochemometric models, protein and ligand descriptors are generated 
independently and do not require ligand-receptor complexes. A PCM modeling 
workflow describing the approaches used in this thesis is shown in Figure 13. 
The advantage of using protein descriptors in PCM models comes mainly from 
their ability to extrapolate to novel chemical and target space (Van Westen et 
al., 2011; Cortés-Ciriano et al., 2015).  
 
Apart from the large-scale applications of PCM in modelling the bioactivities of 
many drug targets (Prusis et al., 2001; Lapins et al., 2002; Strömbergsson et al., 
2006; Kontijevskis et al., 2008; Lapins et al., 2008; Prusis et al., 2008; 
Kontijevskis, A. et al., 2009; Lapins et al., 2010; Fernandez et al., 2010; Bruyn 
et al., 2013; Ain et al., 2014; Cortes et al., 2015; Paricharak et al., 2015; De 
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Rasti et al., 2016; Simeon et al., 2016), its suitability to model antigen-antibody 
interactions (Mandrika et al., 2007; Dimitrov et al., 2010; Dimitrov et al., 
2015), predict ligand binding free energies (Kramer et al., 2011), investigate 
spectral properties of fluorescent proteins (Nantasenamat et al., 2014) and 
utilize omics data to predict drug sensitivities against cancer cell lines (Cortés-
Ciriano et al., 2015) makes proteochemometrics a promising approach. 
Reviews by Van Westen et al. and Cortes-Ciriano et al. summarize all PCM 
studies conducted up to 2013, together with the commonly employed machine 
learning approaches in PCM (Van Westen et al., 2011; Cortés-Ciriano et al., 
2015). Some of the recently conducted studies (beyond 2013) are reported in 
Table 3. 
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Although the usefulness of PCM is usually shown theoretically based on the 
model’s predictabilities and interpretabilities, there are also instances where 
follow-up experimental validations (Table 4) have been done to demonstrate 
the successful applications of PCM in compound design. 
 
Table 4. Examples of prospective validations of PCM models. 
 
PCM study Experimental validation / Inference Reference 
SVM modelling of GPCRs 
and kinases 
Novel scaffolds were identified by 
PCM:  3 agonists and 6 antagonists for 
ADRB2 and 5 inhibitors for EGFR 
Yabuuchi et 
al., 2011 
SVM modelling of HIV 
reverse transcriptase 
mutants 
Experimental measurements of EC50 for 
317 protein-ligand pairs shows a 
correlation of 0.69 with the EC50 
predicted by PCM models; PCM 
models outperform both QSAR and 
KNN, with an increase in R02 by 40-
60% 
Van Westen et 
al., 2011 
RF modelling of oxytocin 
receptor 
Experimental testing of 128 compounds 
resulted in 10 hits with >20% inhibition 
at 10 ?M concentration; 6 hits retrieved 
from chemogenomics screening, 
including 2 potent antagonists (87 and 
38% inhibition at 10 ?M concentration) 
 
 
 
 
Weill et al., 
2011 
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PCM study Experimental validation / Inference Reference 
RF modelling of 
OATP1B1 and OATP1B3 
receptors 
Comparison of model predictions and 
experimental validations of 54 
compounds shows that OATP1B1 and 
OATP1B3 inhibitors can be correctly 
classified as actives and inactives with 
80% and 74% accuracy, respectively. 
De Bruyn et 
al., 2013 
RF - Random Forest; SVM - Support Vector Machine; KNN - K-Nearest Neighbour
 
3.2.1 Protein descriptors in PCM modelling 
Protein descriptors that explain the characteristics of a target’s binding site can 
be derived from either the amino acid sequences or from the 3D structures. 
Some of the commonly used sequence-based descriptors include Z-scales 
(Sandberg et al., 1998), FASGAI (Liang et al., 2008) descriptors that account 
for physicochemical properties, T-scales (Tian et al., 2007) and ST-scales 
(Yang et al., 2010) that describe topological properties and BLOSUM matrix-
derived amino acid descriptors (Georgiev, 2009). A benchmarking study by 
Van Westen et al. (2013) shows that Z-scale descriptors generate the best-
performing models, and this is in line with the increased use of Z-scale 
descriptors in sequence-based PCM studies conducted to date (Van Westen et 
al., 2011; Cortés-Ciriano et al., 2015).  
 
Although structure-based descriptors are not frequently used in PCM 
modelling, the additional information captured by the 3D descriptors and visual 
interpretability open up new opportunities for future developments in 3D PCM. 
Some typical examples of the 3D descriptors used in PCM studies include local 
substructures of proteins (Strömbergsson et al., 2006; Strömbergsson et al., 
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2008) and pharmacophoric properties of binding cavities (Weill and Rognan, 
2009; Meslamani et al., 2012; Shaikh et al., 2016). 
 
None of the descriptors discussed in this section are used in our studies. 3D 
field-based descriptors used in this thesis are explained in detail in the Methods 
section.  
 
3.2.2 Ligand descriptors in PCM modelling 
Ligand descriptors can either be 2D descriptors, comprising the ligand’s 
physicochemical properties and molecular connectivity, or 3D descriptors, 
allowing the conformational space and stereochemistry of the ligands to be 
explored (Damale et al., 2014). A wide array of descriptors available for 
explaining the ligand space is compiled in the “Molecular Descriptors for 
Chemoinformatics” book by Todeschini and Consonni (Todeschini and 
Consonni, 2009). The choice of the ligand descriptors to be used for PCM 
modelling is purely subjective and depends on the dataset (similarity or 
dissimilarity between ligands), flexibility of the ligands and interpretability.  
 
In PCM studies, the most commonly used ligand descriptors are circular 
fingerprints that take into account the molecule’s connectivity and chemical 
features by considering neighbouring atoms within a certain diameter 
(http://www.rdkit.org). These descriptors are mainly used for their simplicity 
and good model predictabilities (Van Westen et al., 2011; Cortés-Ciriano et al., 
2015). Apart from circular fingerprints, 3D Grid INdependent Descriptors 
(GRIND) is also frequently used to provide spatial representation of molecules 
and enhance interpretability. GRIND descriptors are alignment-independent 
variables, resulting from the transformation of molecular interaction fields 
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derived from several probes that describe the hydrogen bonding and 
hydrophobic properties of a molecule (Pastor et al., 2000). Despite the frequent 
usage of certain ligand descriptors, several PCM studies have used multiple 
ligand descriptors and compared the model performances based on the 
predictabilities during internal and external validations (Weill and Rognan, 
2009; Huang et al., 2012; Gao et al., 2013; Shiraishi et al., 2013; Cortés-Ciriano 
et al., 2015). Ligand descriptors used in this thesis are summarized in Table 5 of 
the Methods section. 
 
3.3 Perspectives on QSAR / PCM modelling 
Despite the popularity and usefulness of QSAR and PCM modelling 
approaches in drug discovery, there are some limitations inherent to these 
predictive modelling techniques. Experimental errors and errors during data 
curation can have a significant impact on the model quality (Dearden et al., 
2009). One of the commonly encountered problems in QSAR / PCM modelling 
is the error in descriptor calculations resulting from incorrect chemical 
structures and the discrepancies in values calculated by different software 
(Dearden et al., 2009). Other sources of error arise from insufficient training 
data and the use of incorrect statistics for model evaluation. The pitfalls of 
using q2 based on LOO validation and R2 based on training data as the only 
measures to evaluate model performances have been discussed in Tropsha et al. 
(2001) and Alexander et al. (2015), respectively. Another well-known problem 
is model overfitting, owing to the use of excessive numbers of descriptors in 
model training (Topliss and Costello, 1972).   
 
QSAR models can be useful only if the descriptors reflect the actual 
phenomena (Johnson, 2008). The choice of descriptors is crucial to acquire a 
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meaningful interpretation of the models. Even though 2D descriptors are widely 
used in QSAR / PCM modelling, failure to account for the spatial 
representation of the molecules limits their usefulness. On the other hand, using 
3D descriptors also entails limitations such as incorrect 3D conformations 
(Guimarães et al., 2016) used for descriptor calculations, limited exploration of 
the ligand conformational space (Cappel et al., 2015) and need for bioactive 
conformations for CoMFA models (Cramer et al., 1988).  
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Aims of this thesis 
 
The main objective of this thesis was to deal with the limitations inherent to 
sequence-based PCM models that lack visual interpretability. To this end, we 
developed field-based proteochemometrics and applied this method to model 
the bioactivities of kinase and serine protease families. We used field-based 
protein descriptors and several 2D / 3D ligand descriptors to generate 
proteochemometric models that are visually interpretable. Extensive validations 
were conducted to support the credibility of the models and their usefulness for 
real-time purposes.  
Specific aims were as follows: 
1. To demonstrate the possibilities of applying field-based descriptors in 
proteochemometric modelling using kinases as a specific example 
(Publication I) 
- To build models on continuous bioactivity data using knowledge-
based and WaterMap fields derived from kinase binding sites and 
2D ligand descriptors  
- To visualize the features identified as important for binding affinity 
and selectivity 
2. To investigate the prediction capabilities of field-based proteochemometric 
models on kinases (Publication II) 
- To build global classification models to predict active and inactive 
ligands 
3. To use information-rich 3D descriptors for both kinases and ligands and to 
extend the application of field-based proteochemometric approaches to 
study the features relevant for the selectivity of serine proteases 
(Publication III) 
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- To build predictive and visually interpretable models on a set of 24 
serine proteases and 5863 inhibitors 
- To perform extensive validations, such as Leave One Target Out 
(LOTO) and Leave One Compound Cluster Out (LOCCO), to 
investigate the extrapolative power of the models in terms of target 
and chemical space 
4. To investigate the influence of protein superimposition on field calculations 
- To use alignment-independent Zernike descriptors for proteins in 
proteochemometric modelling 
- To evaluate the prediction performances of the models based on 
protein fields and Zernike descriptors (unpublished results) 
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Materials and Methods 
This section includes a short description of the materials and methods used in 
this thesis. Detailed explanations concerning the methods are available in the 
original publications (I – III).  
 
1 Data collection 
1.1 Interaction data 
The experimental data used in proteochemometric modelling were mainly 
extracted from scientific literature and public databases such as ChEMBL and 
Kinase SARfari. ChEMBL (Bento et al., 2014) is an open source database that 
includes the bioactivity data of ?2 million compounds (small molecules, 
peptides and antibodies) and about 11000 targets. Additional information about 
assay conditions, patents and literature references make this database a useful 
resource for conducting large-scale virtual screening and chemogenomics 
studies (Bento et al., 2014). Kinase SARfari is a resource dedicated to support 
chemogenomics research on kinases by integrating the information about 
sequences, 3D structures and bioactivities 
(https://www.ebi.ac.uk/ChEMBL/sarfari/kinasesarfari). In Publication I, the 
interaction data (Kd / Ki) for 50 kinases and 80 inhibitors were extracted from 
three publications (Karaman et al., 2008; Davis et al., 2011; Metz et al., 2011). 
In Publication II, activity data (Kd, Ki, inhibition% and residual activity) for 95 
kinases and 1572 inhibitors were compiled from a variety of sources, including 
the literature used in Publication I, Kinase SARfari and ChEMBL 18 (GSK and 
Millipore screening data). In Publication III, bioactivity data (Ki) for 24 
proteases and 5863 inhibitors were extracted from ChEMBL 20. ChEMBL 18 
and 20 mentioned here correspond to the different versions of ChEMBL. 
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1.2 Criteria for ligand selection 
In Publication I, we applied some criteria to choose the kinase inhibitors that 
have the potential to bind to either DFG-in/active or DFG-out/inactive 
conformations of kinases. Since our models were mainly focused on the DFG-
in conformations, we carefully extracted the DFG-in-like inhibitors based on 
the literature and by performing a fingerprint-based similarity search to known 
DFG-in inhibitors. Similarity searches based on Extended-connectivity 
fingerprints such as ECFP4 hardly found any DFG-in like inhibitors, owing to 
the diverse nature of compounds in the kinase dataset. Therefore, the commonly 
used MACCS keys (Durant et al., 2002) that rely on the predefined SMARTS 
patterns are an ideal choice for conducting fingerprint-based searches. In 
addition to filtering the DFG-in-like inhibitors, we removed compounds that 
had activity data for less than three kinases. In Publications II and III, no 
specific compound selection criteria were applied. All data available in the 
literature and public databases were used to build global predictive 
proteochemometric models for kinases and serine proteases. 
 
1.3 Ligand structures 
Ligands collected from scientific literature were downloaded from PubChem 
database in SDF format, whereas the structures of ligands from ChEMBL and 
Kinase SARfari were generated in Maestro (Schrödinger, 2011) based on their 
SMILES notation. Schrödinger’s LigPrep module was then used to convert 2D 
structures to 3D and generate possible ionization states at pH 7.0? ????. To 
explore the conformational space further, ConfGen’s (Watts et al., 2010) 
conformation generation module was employed. The force fields used in 
ConfGen were OPLS-2001 for initial structure generation and OPLS-2005 for 
energy minimization. From the multitude of conformations generated for each 
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ligand, the lowest energy conformation was chosen for 3D descriptor 
calculations. 
 
1.4 Protein structures 
X-ray structures of kinases (95) and proteases (24) used in this study were 
downloaded from PDB. The completeness of the structures (no missing 
residues within 5Å of the crystal ligands) together with the resolution (< 3 Å) 
was used as the main criterion for choosing structures. Initially, the protein 
structures were cleaned by removing water molecules, additional chains and 
ligands. A standard protocol defined by the nodes in a KNIME workflow was 
used for protein preparation. KNIME (Berthold et al., 2007) is an open source 
workflow tool with a wide range of applications, including data mining, text 
processing, sequence analysis and statistical data analysis. An advantage of 
using KNIME is the possibility to integrate the modules provided by 
commercial vendors like Schrödinger and MOE. The workflow used for protein 
preparation included the following steps: (1) Correct residues with missing 
atoms, (2) Add hydrogen atoms, (3) Assign protonation states to ionizable 
residues based on the pH values determined from pKa predictions of PROPKA, 
(4) Optimize the geometry of hydrogen atoms, keeping heavy atoms fixed.  
 
2 Protein superimposition 
Protein superimposition is a procedure used to align protein structures to enable 
easy comparison. Following superimposition, the orthosteric binding pockets fit 
on top of each other, which makes them suitable for field comparisons. We 
used Schrödinger’s protein structure alignment tool that relies on dynamic 
programming to provide a best fit based on the sequence and secondary 
structural elements and to minimize the RMSDs of C? atoms. The common 
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reference structures used for superimposing kinases and proteases were c-Met 
kinase (PDB: 3A4P) and Matriptase (PDB: 1EAX), respectively. 
 
3 Methods for protein descriptor calculations 
3.1 Knowledge-based fields 
The ligand binding sites of kinases and serine proteases were described by 
fields derived from the knowledge-based contact potentials calculated by MOE. 
Knowledge-based contact potentials (Figure 9) are the joint probability 
densities derived from interatomic distance, lone-pair interaction angle and out-
of-plane angle (MOE, 2011). The joint probability densities are expressed by  
                  Pr (Ligand = l | Position = x, Protein = p)    
  
The hydrophilic and hydrophobic contact probabilities are calculated by 
considering the conditional probability of observing a ligand atom l at position 
x, provided the ligand atom l is in contact with the protein structure p. In 
knowledge-based field calculations, preferences for hydrophilic and 
hydrophobic contacts are determined based on the protein crystallographic data 
available in PDB (MOE, 2011). An advantage of using the knowledge-based 
contact potentials is that the directional preferences are taken into account and 
additional information is provided for describing the target-ligand interaction 
space.  
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Figure 9. Contact maps of selected ligand atoms and amino acid residues. Hydrophilic 
and hydrophobic contact maps are shown in red and green, respectively. Figure 
created using MOE (Molecular Operating Environment) is reproduced with 
permission from Chemical Computing Group                     
(https://www.chemcomp.com/journal/f_surfmap.htm). 
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In our studies, we calculated the knowledge-based fields by spanning a grid 
around the binding site. The crystal ligands extracted from PDB structures 
determined the size of the grid. For kinases, the dimensions of the grid were 
defined by 41 X-ray ligands (Publications I and II). For serine proteases, the 
peptide-like inhibitor that extends across the S1-S4 sub-pockets of Activated 
Protein C crystal structure (PDB: 1AUT) was used as the reference for grid size 
definition (Publication III). The space between the grid points was set to 0.5??. 
The hydrophilic and hydrophobic contact probabilities were calculated at every 
grid point and were influenced by the neighbouring atoms (Figure 10). The 
contact probabilities that exceeded the 0.9 thresholds were used as descriptors 
in proteochemometric modelling (Figure 11). 
 
Figure 10. Schematic representation of the grid enclosing the ligand-binding site of 
ABL1 kinase. Blue and orange spheres with varying colour intensities correspond to 
the polar and lipophilic field points with different contact probabilities. Figure adapted 
with permission from (Subramanian, V.; Prusis, P.; Pietilä, L. O.; Xhaard, H.; 
Wohlfahrt, G. Visually Interpretable Models of Kinase Selectivity Related Features 
Derived from Field-Based Proteochemometrics. J. Chem. Inf. Model. 2013, 53, 3021–
3030). Copyright (2013) American Chemical Society. 
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Figure 11. Knowledge-based fields calculated from the ligand-binding site of ALK 
kinase. The inhibitor TAE-684 extracted from the X-ray structure 2XB7 is shown as 
reference. Only the fields that lie in close proximity to the inhibitor are shown for 
clarity. Left panel: Polar protein fields with probability density > 0.9. Right panel: 
Lipophilic protein fields with probability density > 0.9. 
 
3.2 WaterMap-derived fields 
Schrödinger’s WaterMap (WaterMap, 2012; Abel et al., 2008) can be used to 
predict the position of water molecules in the binding site. WaterMap 
calculations are based on molecular dynamics simulations that involve explicit 
water molecules. The predicted water sites are assigned statistical 
thermodynamic properties such as enthalpy, entropy and Gibb’s free energy 
that are likely to influence ligand binding. Displacement of entropically 
unfavourable water molecules in the binding site facilitates ligand binding and 
maximizes affinity (Abel et al., 2008; Michel et al., 2009). Therefore, analysing 
the position and energetics of the water molecules is crucial in drug design. 
 
We have calculated the WaterMaps for the kinase and serine protease binding 
sites (Figure 12a) and projected them onto the knowledge-based grids to derive 
WaterMap fields (Figure 12b, c) (Publications I-III). Water density values were 
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initially assigned to the grid points to extract the high-density regions (density > 
0.06). Gibb’s free energy value was subsequently assigned to classify these grid 
points as stable (?G < -1 kcal/mol) or unstable water fields (?G > 3 kcal/mol), 
which were later used as descriptors in proteochemometric modelling. 
 
 
 
Figure 12. (a) WaterMaps calculated from the ligand-binding site of ALK kinase. The 
inhibitor TAE-684 extracted from the X-ray structure 2XB7 is shown as a reference. 
Water molecules with ?G < -1 kcal/mol (stable - green) and ?G > 3 kcal/mol (unstable 
- red) are highlighted with larger spheres. (b) Unstable water fields with ∆G > 3 
kcal/mol. (c) Stable water fields with ∆G < -1 kcal/mol. 
 
3.3 Zernike descriptors 
Zernike descriptors (Novotni and Klein, 2003) are alignment-independent 
descriptors commonly used for shape retrieval and comparison of ligand 
binding sites (Nisius and Gohlke, 2012). These descriptors are a vector of 
coefficients of terms in the Zernike polynomial expansion series and are 
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insensitive to misalignments of binding sites. We have calculated Zernike 
descriptors using our in-house scripts by transforming the knowledge-based and 
WaterMap-derived fields through a series expansion in 3D Zernike 
polynomials. Zernike function can be represented as 
????????? =? ? ? ???? ? ????????????????? ?????????                           Eq.1 
where ???????? is the field vector, ????  is the Zernike moment, ????  is the Zernike 
polynomial and N is the maximum number of expansion terms. n, l and m in 
Eq.1 correspond to the principal, azimuthal and magnetic quantum numbers, 
respectively. 
 
Zernike descriptors were computed with varying orders of N (3, 5, 10, 20, 30, 
40, 50) and used as protein descriptors in PCM modelling. 
 
4 Ligand descriptors 
Both 2D and 3D ligand descriptors were used for proteochemometric modelling 
(Table 5). This includes Open Babel’s (Boyle et al., 2011) FP4 fingerprints 
(Publications I and II), Mold2 (Hong et al., 2009) descriptors (Publications I and 
II), Volsurf (Cruciani et al., 2000) descriptors (Publication I), 4-point 
pharmacophoric fingerprints (4-PFP) from Canvas (Canvas, 2014; Duan et al., 
2010) (Publications II and III), MOE (MOE, 2015) descriptors (Publication III), 
RDKit fingerprints (http://rdkit.org) (Publication III) and Pentacle’s GRIND 
descriptors (Pastor et al., 2000) (Publication III).  
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Table 5. Ligand descriptors for PCM modeling. 
 
Descriptor Information encoded 
2D descriptors 
Open Babel FP4 
fingerprints 
Atom and bond properties assigned based on predefined 
SMARTS patterns 
Mold2 Counts of atoms and bonds, physicochemical properties 
and topological descriptors 
MOE descriptors Counts of atoms and bonds, physicochemical properties 
and descriptors that account for molecule’s topology, 
pharmacophore features and partial charges 
RDKit fingerprints Circular fingerprints that describe molecule’s connectivity 
and chemical features 
3D descriptors 
Volsurf Physiochemically relevant numerical descriptors derived 
from GRID molecular interaction fields calculated based 
on water, hydrophobic and hydrogen bond acceptor 
probes 
4-PFP Pharmacophoric fingerprints based on the hydrogen bond 
donor (D), hydrogen bond acceptor (A), hydrophobic (H) 
and aromatic ring features (R) 
GRIND Alignment-independent variables obtained from the 
transformation of molecular interaction fields calculated 
using hydrogen bond donor (O), hydrogen bond acceptor 
(N1) and hydrophobic (DRY) probes 
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5 Data pre-processing 
Descriptors with near-zero variance were removed to reduce random noise. 
Presence of multiple classes of descriptors could introduce bias in the 
modelling process, which makes it necessary to apply the scaling and centring 
techniques. All of the descriptors were centred and scaled to unit variance 
(UV). In UV scaling, the descriptors are multiplied by the base weight, which is 
the inverse of the standard deviation calculated for each descriptor column. 
Additionally, block scaling (SIMCA, 2011) was applied for the descriptors in 
PLS models. Each descriptor class was considered as a separate entity called a 
block. In case of block scaling, each variable was multiplied by the block 
weight 1/?b, where b is the number of variables in each block. 
 
6 Principal Component Analysis 
Principal Component Analysis (PCA) (Wold et al., 1987) is a dimensionality 
reduction technique that involves orthogonal transformation of variables. The 
projection of variables to a lower dimensional space transforms them into 
linearly uncorrelated variables and they constitute the principal components 
(PCs). The transformed values for each data point constitute the PC scores, and 
the weights that explain the contributions of original variables towards the PC 
score calculations represent the loadings. PCA enables one to visualize the 
variation in data. We have applied PCA to both protein and ligand descriptors 
(Publications I-III). 
 
7 Cross-term descriptors in proteochemometric modelling 
Cross-terms (Wikberg et al., 2004) are commonly used to introduce non-
linearity in models that use linear approaches like PLS. Cross-terms can be 
computed as a product of protein-protein or ligand-ligand or protein-ligand 
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descriptors. Protein-protein and ligand-ligand cross-terms account for the 
intramolecular interactions in target and ligand space, respectively, whereas, 
protein-ligand cross-terms that explain the intermolecular interactions between 
proteins and ligands facilitate understanding of selectivity. Only the protein-
ligand cross-terms are used in our studies (Publications I and III). 
 
8 Generation of training and test sets 
The reliability of the PCM models can be best assessed by training the models 
on a dataset (training set) and using them to predict the bioactivities of a new 
set (test set) that has not been used in training the model. The training and test 
sets in PCM models can either be generated randomly (Publication III) or 
selected carefully after performing a diversity analysis on the dataset 
(Publication II). Training and test sets used for PCM modelling in different 
publications are presented in Table 6. 
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9 Machine learning approaches 
9.1 Partial Least Squares Regression 
Partial Least Squares (PLS) (Geladi et al., 1986; Wold et al., 2001) regression is 
a linear modelling technique used to study the correlation between a set of 
independent/predictor variables (X) and one or more dependent/response 
variables (Y). The PLS components are extracted by projecting both X and Y 
variables into new spaces to explain the maximum covariation between X and 
Y. In Publications I and III, we used the PLS approach to model the correlation 
between protein/ligand descriptors (X) and experimental binding affinities (Y). 
The equation describing the protein-ligand interactions in PLS models can be 
expressed as follows (Lapinsh et al., 2005): 
 
?? ? ?? ?? ?????????? ? ?? ? ? ?????????? ? ?? ? ? ?????????????????? ? ?? ? ?? Eq.2 
 
where Yc is the computed Y value, Ym is the mean Y value, xl is the ligand 
descriptor matrix, xp is the protein descriptor matrix and xl*xp is the cross-term; 
coeffl, coeffp and coeffl,p are the regression coefficients of ligands, proteins and 
cross-terms, respectively.  
 
9.2 Random Forests 
Random Forests (RF) (Breiman, 2001) are non-linear machine learning 
approaches dependent on an ensemble of decision trees to generate predictive 
models. A decision tree is a tree-like model that includes a series of decisions 
and possible outcomes. Using a single decision tree could lead to biased 
modelling and affect the prediction accuracies. Growing a random forest of 
decision trees by selecting random subsets of attributes from the feature space 
could significantly boost the model performances. The RF approach employs a 
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bagging algorithm where subsets of samples are randomly excluded to estimate 
the prediction errors. RF models are robust, as they are not strongly dependent 
on data pre-processing strategies and are less sensitive to outliers and noise. RF 
was used for training classification models in Publication II and regression 
models in Publication III. 
 
9.3 Support Vector Machines 
Support Vector Machine (SVM) (Cortes and Vapnik, 1995) is a machine 
learning approach that aims to construct hyperplanes to maximize the 
separation between different classes of data. For data that are not linearly 
separable, SVMs project the data to a high-dimensional feature space by 
employing kernel tricks. SVMs rely on many different kernel functions, some 
of which include radial basis function kernel, polynomial kernel, linear kernel 
and string kernels. The kernel functions differ by the parameters used and the 
way in which the feature mapping is performed. Optimizing the kernel 
parameters is critical in SVM modelling to find the optimal classifier.  We have 
used SVM to train classification models on a kinase dataset to separate actives 
and inactives (Publication II). 
 
10 Model validation 
10.1 Cross-validation 
Validating the models is crucial to assess their robustness. One of the 
commonly used internal validation procedures is cross-validation (CV), where a 
subset of data is excluded from the modelling process and used as an external 
test set. The different variants of cross-validation include 
(i) K-fold CV: Data are split into k subsets. The model is trained on k-1 
subsets and tested on the omitted set. This procedure is repeated, 
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until each of these subsets is tested once. The K-fold CV approach is 
frequently used in model validation. 
(ii) Leave One Out validation (LOO): It is an exhaustive validation 
procedure, where each and every observation is excluded for testing 
and the model is trained on the remaining observations. This 
approach is not so robust and the studies have shown that using 
LOO as the only validation approach is not optimal, but using it in 
combination with other validation techniques could be useful 
(Golbraikh et al., 2001). 
(iii) Leave One Target Out Validation (LOTO): The observations 
corresponding to the targets used in PCM modelling are excluded 
one at a time to evaluate the model’s extrapolation capabilities in 
terms of target space.  
(iv) Leave One Compound Cluster Out validation (LOCCO): The 
observations corresponding to a compound cluster (compounds 
grouped together based on their descriptor space) are excluded to 
assess the model’s prediction performances on a new compound 
space. 
(v) Double CV: It is a nested CV approach, where the validations are 
conducted by considering outer and inner loops. In the outer loop, 
the dataset is split randomly into training and test sets. The training 
set is validated by dividing it into k subsets in the inner loop to 
choose the optimal model for external test set predictions. Double 
CV provides a robust way to validate the models. 
(vi) Repeated random subsampling: Also known as the Monte Carlo 
method, where the validations are performed multiple times on 
different random splits of training and test sets. This method has the 
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disadvantage of choosing the same observation numerous times and 
excluding some observations completely from the validation cycles. 
K-fold CV (7-fold in Publication I, 5-fold in Publications II and III), LOTO 
(Publication I and III) and LOCCO (Publication III) are the validation 
procedures used in our studies. 
 
10.2 External prediction 
A model that performs well in internal cross-validation does not ensure its 
predictability on a completely external test set (Golbraikh et al., 2002). So, 
there is a need to assess the external predictive power of the models by either 
acquiring a new set of observations (Publication I) or by dividing the existing 
dataset into training and test sets (Publications II and III).  
 
10.3 Permutation validation 
Permutation validation / Y scrambling (Eriksson et al., 1997) is a procedure 
generally used to evaluate model overfitting. Models dependent on a large 
number of descriptor variables can often result in spurious correlations (Topliss 
and Costello, 1972; Eriksson et al., 1997) and perform poorly when applied to 
an external test set. Therefore, it is necessary to validate the models on random 
data. We have conducted permutation testing 20 times by fitting the models to 
random data generated by reordering experimental affinity values (Publication 
I) or activity classes (Publication II).  
 
11 Model performance 
In the assessment of the continuous model performances (Publications I and III) 
based on internal cross-validations, external predictions and permutation 
validations, the following measures were used: 
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Correlation coefficient (R2) and Predictability (Q2): R2 is a measure used to 
estimate the agreement between the observed and calculated values of the 
training data. 
?? ? ? ? ? ?????????????????????????
????                                      Eq.3  
 
Here, ?? refers to the observed measurements and ???  is the mean value of all of 
the observed measurements. 
 
Q2 is an estimate of the correlation between the observed and predicted values 
during CV rounds. 
?? ? ? ? ? ?????????????????????
????                                          Eq.4 
Here, ?? refers to the observed measurements of the subset excluded during CV; 
???????  corresponds to the predicted values during cross-validation and ???  is the 
mean value of all of the observed measurements. 
 
Root Mean Square Error of Estimation (RMSEE): Prediction errors computed 
by comparing the calculated values (Ycalculated) of all of the observations (N) 
used for modelling with the experimentally measured values (Yi) 
????? ? ? ???????????????????????                                Eq.5 
 
Root Mean Square Error of Prediction (RMSEPCV): Prediction errors 
computed by comparing the values of all of the observations (N) predicted 
during CV rounds (YPredCV) with that of the experimentally measured values 
(Yi) 
??????? ? ? ?????????????
?
?
????                                Eq.6 
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Root Mean Square Error of Prediction (RMSEPtest): Prediction errors 
computed by comparing the values of all the observations (N) predicted for an 
external test set (YPredicted) against the experimentally measured values (Yi) 
????????? ? ? ????????????????
?
?
????                              Eq.7 
 
Assessment of Permutation validation results 
The intercepts obtained by plotting the correlation coefficients of the original 
and permutated values against the correlation (R2) and predictability (Q2) values 
were used as the basis of assessing permutation validation (Figure 14). R2 
intercepts below 0.3 and negative Q2 intercepts imply that a model is valid 
(Eriksson et al., 1999) enough for further predictions and interpretations. 
 
 
Figure 14. An example of permutation validation conducted on serine protease dataset. 
Permutation plots shown here correspond to the PLS models based on protein fields 
and RDkit fingerprints. Colored dots in the figure correspond to the R2 and Q2 values 
of the 20 models built with randomly permuted Y values. 
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For classification models, the performances were evaluated by computing 
several measures (accuracy, sensitivity/true positive rate, specificity/1-false 
positive rate, Matthews correlation coefficient (MCC) (Matthew, 1975), kappa 
coefficient (Cohen, 1960) and area under the ROC curve (AUC) (Linden, 
2006)) dependent on the number of true positives (TP), false positives (FP), 
true negatives (TN) and false negatives (FN).  
??????????? ? ????????????????                                     Eq.8 
??????????? ? ???????                                                     Eq.9 
??????????? ? ???????                                                   Eq.10 
??? ? ???????????????????????????????????????????                 Eq.11 
???????????????? ? ?????????????????????????????????????????         Eq.12 
 
where ??????????????? ? ????????????????????????????????? ; N is the total 
number of observations. 
 
AUC: AUC refers to Area Under the Curve and it is a measure of a classifier’s 
potential to rank true positives higher than false positives; AUC values are 
estimated based on the ROC curve, which is a plot of the false-positive rate 
(FPR) against the true-positive rate (TPR) (Figure 15). AUC of 1 implies that 
the classification is perfect, and AUC of 0.5 indicates randomness. 
 68 
 
 
Figure 15. ROC curves of the SVM classification models of the kinase dataset shown 
relative to the ROC curves with random and maximum AUCs. 
 
12 Model interpretation 
12.1 Interpretation of PLS models 
PLS models were interpreted by analysing the features that have a positive 
influence on binding affinity (Publications I and III). Protein and ligand 
descriptors related to affinity of ligands towards kinases/proteases were 
identified based on the positive PLS coefficients (coeffl and coeffp as described 
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in Eq. 2). Further, to interpret the features related to selectivity, we used cross-
term coefficients (coeffl,p in Eq. 2). The descriptors used in PCM modelling 
being the PC scores, the original protein field points and ligand functional 
groups / fingerprints were traced back by examining the loadings of the PCs. 
Since interpretation of the protein field points is a laborious process, we 
restricted the interpretation to positive PLS coefficients and analysed only the 
top 10 loadings of PCs.  
 
12.2 Interpretation of RF models 
In RF models, Gini index and the descriptor’s correlation to active class were 
used as the basis for interpretation (Publication II). Gini indices are a measure 
of the homogeneity of the nodes and depend on the variables used for splitting 
in decision trees. The higher the decrease in Gini index, the more the descriptor 
has relevance for classification (Liaw, 2002). However, the Gini indices fail to 
account for the descriptor’s relevance for active or inactive class. Subsequently, 
the descriptors that had high correlation values for the active class were selected 
for interpretation. The protein field points and ligand’s 4-PFPs that make a 
ligand active or inactive towards a specific kinase were identified by analysing 
the loadings of PCs, as described above. 
 
13 Applicability Domain (AD) analysis 
A model’s usefulness can be evaluated by its capability to predict new targets 
and ligands that have not been used in the modelling process. The scope and 
accuracy of predictions can be ascertained based on the similarity of the 
external ligand or target to its training space (Jaworska et al., 2005).  
 
 
 70 
13.1 Ligand space 
In Publications II and III, the AD analysis was conducted by inspecting the 
Tanimoto similarities of the test set ligands based on their fingerprints against 
the training set compounds.  
 
???????????????????? ? ???? ????????????? ?                             Eq.13 
 
Here, ???? ? is the number of bits found in both training and test set ligands; 
NTr is the number of bits found only in the training set ligand and NTe is the 
number of bits found only in the test set ligand. 
 
The similarity thresholds ideal for reliable predictions of the test set ligands was 
determined by considering their prediction accuracies (> 80%) in Publication II 
and RMSEPs in Publication III (RMSEPtest < 1). 
 
13.2 Target space 
The extent to which the models can be applied to understand polypharmacology 
depends on their extrapolative power. Extrapolation to novel targets was 
assessed by computing the Euclidean distance between the training and test set 
kinases, based on the PC scores of protein field descriptors (Publication II). 
Euclidean distances were calculated by using the following formula: 
 
?????????????????? ? ?? ?????? ? ???????????                Eq.14 
 
where KinTr and KinTe refer to the protein descriptors of training and test set 
kinases, respectively. 
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Summary of main results 
1 Characterization of datasets 
The ligand, target and bioactivity space of the kinase and serine protease 
datasets were analysed by considering the description of the molecules, 
knowledge-based and WaterMap-derived fields of the protein’s binding pockets 
and the distribution of bioactivities, respectively. Ligand space was analysed 
only by considering the descriptors that gave the best performance in PCM 
modelling (for details, see Table 8 and 10) 
 
1.1 Kinase dataset 
Ligand space 
In Publication I, clustering 80 ligands based on the Euclidean distances 
computed from the PC scores of Open Babel fingerprints shows that there are 
many compounds that overlap in terms of chemical space, which in turn limits 
the diversity of the dataset. Ligands clustered together based on chemical space 
have different propensities towards kinases (Figure 16), which makes it rather 
difficult to predict the bioactivities of new compounds. Among the 80 ligands 
for which activity data are known for all 50 kinases, 29 ligands are highly 
selective, interacting with less than 5 kinases. Nearly 20% of the ligands are 
non-selective, the most promiscuous being staurosporine, which interacts with 
47 out of 50 kinases in the dataset. Considering the grouping patterns of ligands 
based on their selectivity, no distinct clusters are observed with respect to 
ligands that act on 5 kinases or 40 kinases.  
 
In Publication II, the dataset was extended to include 1572 inhibitors. Principal 
component analysis based on 4-PFPs shows the uniform distribution of the 
compounds in the PC space, which in turn reflects the diversity of the dataset. 
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Sixty-two PCs that explain 80% of the total variation in data were extracted to 
be used in PCM modelling. For simplicity, only two PCs that explain 33% of 
the variance are shown here (Figure 17). Further, comparing the distributions of 
Tanimoto similarities of the training and test ligands (Figure 18) shows that 
nearly 80% of the test set ligands have Tanimoto similarities above 0.7 with the 
training set ligands. The overlap in chemical space between the training and test 
set compounds is comparatively higher than the similarities among the training 
set compounds, supporting the reliability of the test set predictions. 
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Figure 16. Hierarchical average linkage clustering of 80 kinase inhibitors based on 
their Open Babel fingerprints (Publication I). Different coloured text in the figure 
corresponds to selectivities of the compounds, categorized by number of kinases, with 
which they are active (Most selective (green): ?5 kinases; Moderately selective 
(black): 6-20 kinases; Least selective (red):?  20 kinases). 
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Figure 17. Scatter plots of the first two principal components of the 4-PFP descriptor 
space of 1572 kinase inhibitors (Publication II). Green and red dots correspond to 
inhibitors in training and test set, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 75 
 
 
 
Figure 18.  Distribution of Tanimoto similarities computed based on the 4-PFPs of 
kinase inhibitors in Publication II. Green bars correspond to the Tanimoto similarities 
among the 1257 ligands in training set; Red bars correspond to the Tanimoto 
similarities of the 315 test set ligands against the training set ligands. 
 
Target space 
As far as the kinase space is concerned (Publications I and II), it includes 
multiple representatives from all of the major kinase families. The knowledge-
based and WaterMap fields seem to be rather similar for various kinase 
subgroups, which is reflected in their clustering patterns (Figures 19 and Figure 
20). For most of the kinase families, the subtypes are grouped together in the 
same cluster. However, there are a few exceptions. For instance, the CDK 
(CDK2, CDK5, CDK9) and PAK (PAK1, PAK6, PAK7) subtypes are placed 
apart in different clusters, despite their high sequence similarity. The even 
spread of different kinase families along the cluster tree together with the 
subgroup similarities enables extrapolation to novel kinases and provides a 
dataset suitable for predicting the activity and selectivity profiles of inhibitors 
0
100
200
300
400
500
600
0.00-0.20 0.21-0.40 0.41-0.60 0.61-0.80 0.81-1.00
Training set ligands
Test set ligands
Distribution of Tanimoto similarities 
 76 
that bind to different kinase subgroups. The 50 kinases in Publication I are a 
subset of the 95 kinases included in Publication II. 
 
 
Figure 19. Similarity heatmaps of 50 kinases derived from the combined knowledge-
based and WaterMap fields (Publication I). The row labels correspond to the various 
kinase subtypes with the family names preceding them. 
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Figure 20. Hierarchical average linkage clustering of 95 kinases derived from the 
combined knowledge-based and WaterMap fields (Publication II). Different colours 
correspond to kinase subfamilies (AGC, CAMK, CK1, CMGC, OPK, STK, TK, TKL). 
Kinases included in the target prediction test set are underlined. Boxes in the cluster 
represent the kinase subtypes grouped together. 
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Activity space 
In Publication I, the bioactivity spectrum of kinases covers a wide range of 
continuous values with pKd / pKis varying from 5 to 11 (Figure 21). Of the total 
of 951 observations considered for modelling, nearly 85% of the interaction 
data falls within the range of 5-8. With only a few highly potent compounds, 
the dataset is imbalanced in terms of pKd / pKi ranges, and it might create a 
challenge for future predictions of compounds with high potencies. 
 
In Publication II, the dataset is compiled from multiple sources and includes 
different types of bioactivities. Therefore, classifying the data points as actives 
and inactives based on certain cut-offs seems to be an optimal choice for 
modelling (Table 7). Analysing the distributions of bioactivity ranges clearly 
shows that nearly 75% of the interaction data belongs to the inactive class 
(Figure 22). This data imbalance is likely to have an impact on the bioactivity 
predictions. 
 
 
Figure 21. Distribution of pKd / pKi values of 80 inhibitors against 50 kinases in 
Publication I  
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Table 7. Distribution of actives and inactives in four different datasets used in 
Publication II 
 
Dataset Interaction data Number of 
data points 
Actives 
(cut-off) 
Inactives 
(cut-off) 
Ambit pKd 5491 1474 (>= 5) 4017 (<5) 
Metz pKi 31667 9151 (>= 5) 22516(<5) 
GSK Inhibition% at 1 ?M 17629 3288 (>=10%) 14341 (<10%) 
Millipore Residual activity 8400 1816 (<=50%) 6584 (>50%) 
 
  
 
 
Figure 22. Distribution of data points (1572 inhibitors and 95 kinases) in four different 
datasets used in Publication II. (a) Ambit (B) Metz (C) GSK (D) Millipore 
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1.2 Serine protease dataset 
Ligand space 
The serine protease dataset of 5863 inhibitors is quite sparse in terms of 
activity. For many inhibitors, interaction data are available only for 1 or 2 
proteases. K-means clustering of the inhibitors based on RDkit circular 
fingerprints resulted in 20 clusters (Figure 23) that had significant overlap in 
chemical space (for details, see Publication III). However, there are a few 
exceptions, with three clusters containing compounds with polycyclic ring 
systems linked to chlorine or fluorine and compounds with pyrazopyrimidines 
remaining distant from the rest. 
 
Figure 23. Distribution of the 20 compound clusters in two dimensions. Different 
colours correspond to different clusters. dc1 and dc2 refer to discriminant coordinates. 
Figure reproduced from Supplementary Material of Publication III. 
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Target space 
Owing to the limited availability of interaction data, the number of serine 
proteases was restricted to 24 in this dataset. Knowledge-based and WaterMap 
fields of the serine proteases resulted in clusters where even some of the 
subgroups are placed apart, e.g. kallikrein 1, 3, 5 and 7 (Figure 24). The low 
similarity between the different proteases and the uneven distribution of data 
points with 70% representing either coagulation factor Xa or thrombin make it 
rather difficult to extrapolate in terms of target space.  
 
Activity space 
Unlike the kinase dataset, the bioactivities of serine proteases are more 
uniformly distributed with the presence of many highly potent and moderately 
potent compounds (Figure 25). Of the 7908 data points used for modelling, 
10% have pKis less than 5, with the majority of the interaction data representing 
kallikrein 7 and coagulation factor XII. Of the data points, 26% have pKis 
ranging from 8 to 11. Most of these highly potent compounds target coagulation 
factor Xa, thrombin, plasma kallikrein and granzyme B. 
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Figure 24. Hierarchical average linkage clustering of 24 serine proteases derived from 
Knowledge-based and WaterMap fields (Publication III). 
 
 83 
 
Figure 25. Distribution of pKi values of 5863 inhibitors against 24 serine proteases in 
Publication III 
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2 Field-based PCM on continuous data 
In Publication I, PCM models were built on a dataset of 50 kinases and 80 
inhibitors with 951 known Kd or Ki values, retrieved from well-curated sources. 
Polar, lipophilic and WaterMap fields were used as protein descriptors together 
with the different 2D (Open Babel, Mold2) and 3D (Volsurf) ligand descriptors. 
PLS models based on ligands’ Open Babel fingerprints showed the best 
performance during both internal cross-validation (Q2: 0.465; RMSEPcv: 0.796) 
and external prediction (RMSEPtest: 0.800). An interesting observation is that 
the cross-terms, introduced to account for non-linearity in PLS models 
improved the model’s overall performance by about 30%, with R2 increasing 
from 0.336 in models without cross-terms to 0.662 in models with cross-terms. 
Also, the predictabilities (Q2) of the models were improved with the inclusion 
of the cross-terms (Table 8). 
 
In Publication III, PCM modelling was conducted on a dataset with pKi values 
extracted for 24 serine proteases and 5863 inhibitors. Field-based descriptors 
were used for proteins, as in Publication I, whereas, ligands were described by 
RDkit fingerprints, MOE descriptors, 4-PFPs and GRIND descriptors. Both 
PLS and RF approaches were used for model training. Considering the model 
performances with respect to different ligand descriptors (Table 8), RF models 
based on RDkit fingerprints had the best performance, with R2 and Q2 as high 
as 0.957 and 0.737, respectively. Further, the RMSEP values from cross-
validation and external test set predictions were below 1, making these models 
more robust. Overall, PLS models had slightly poorer performances than the RF 
models, regardless of the ligand descriptors used. However, the PLS models 
based on RDkit fingerprints performed reasonably well during the model 
training (R2:0.670; Q2:0.588). Their RMSEPtest values were close to 1 and the 
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prediction errors were within the experimental error ranges, which is typically 1 
log unit. Therefore, the models are sufficiently valid to be considered for further 
predictions and interpretations. 
 
Table 8. Performances of field-based PCM models on continuous data. 
 
Ligand 
descriptors 
Method Correlation 
(R2) 
Predictability 
(Q2) 
RMSEPcva RMSEPtestb 
Kinase dataset 
Open Babelc PLS 0.336 0.250 0.954 0.865 
Open Babel PLS 0.662 0.465 0.796 0.800 
Mold2 PLS 0.539 0.445 0.811 0.716 
Volsurf PLS 0.520 0.400 0.842 0.947 
Serine protease dataset 
RDkit 
PLS 0.670 0.588 1.024 1.006 
RF 0.957 0.737 0.799 0.810 
MOE 
PLS 0.505 0.428 1.219 1.129 
RF 0.961 0.703 0.857 0.840 
4-PFP 
PLS 0.543 0.438 1.229 1.136 
RF 0.928 0.566 1.025 0.990 
GRIND 
PLS 0.273 0.238 1.360 1.300 
RF 0.951 0.430 1.175 1.150 
a Root mean square error of prediction resulting from cross-validation 
b Root mean square error of prediction resulting from external test set predictions 
c PCM models without cross-terms 
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3 Influence of protein descriptors in PCM modelling 
Protein descriptors used in PCM models are likely to have an impact on the 
model’s prediction performances. To verify this, performances of PLS models 
based on ligand’s Open Babel fingerprints and different combinations of 
protein fields / sequence-based descriptors were compared in Publication I. 
Building PLS models using knowledge-based fields (polar and lipophilic) or 
WaterMap-derived fields separately did not result in significant variations 
regarding performances. Nevertheless, using these two descriptors in 
combination boosts the model’s overall performance and lowers the prediction 
errors. On comparing the performances of field-based and sequence-based PCM 
models, models derived from sequence information had consistently lower 
predictabilities (Q2: 0.32-0.37) and higher RMSEPs (0.84-0.90) than the field-
based model (Q2: 0.47; RMSEP: 0.80). Similar trends were observed regardless 
of the sequence descriptors used (Table 9). 
 
In Publication III, the effect of including protein descriptors in PCM modelling 
was assessed by building RDkit fingerprint-based models on serine protease 
dataset, where the protein fields were excluded completely. Eliminating protein 
descriptors led to a significant drop in prediction performances (Table 9), with 
R2 and Q2 going as low as 0.5, relative to the models trained with protein fields 
(R2 :0.957 ; Q2: 0.737).   
 
Unlike kinases in Publication I, a slightly different trend is observed with the 
sequence-based PCM models on serine proteases (Publication III). Sequence-
based models perform nearly as well as field-based models in terms of internal 
and external validations (Table 9). However, their limited visual interpretability 
makes them less favourable than field-based models. 
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4 Field-based PCM on classification data 
In Publication II, attempts were made to build a global classification model for 
kinases to test the robustness of the field-based PCM approaches, in terms of 
predictions. RF and SVM models were built on ligand and target prediction sets 
to classify the actives and inactives with Open Babel fingerprints, Mold2 and 4-
PFPs as ligand descriptors. Results of the best-performing RF models are 
reported in Table 10.  
 
Table 10. Performance of field-based PCM models on classification data generated by 
using the Random Forest approach. 
 
Ligand 
descriptors 
Cross-validation External prediction 
Accuracy MCCa AUCb Accuracy MCCa AUCb 
Ligand Prediction dataset 
Open Babel 0.82 0.48 0.86 0.78 0.25 0.73 
Mold2 0.83 0.50 0.88 0.83 0.47 0.85 
4-PFPc 0.83 0.49 0.87 0.81 0.42 0.83 
Target Prediction dataset 
Open Babel 0.83 0.49 0.86 0.80 0.39 0.82 
Mold2 0.83 0.49 0.87 0.81 0.42 0.83 
4-PFPc 0.83 0.49 0.87 0.81 0.41 0.82 
a Matthews correlation coefficient 
b Area Under the ROC curve 
c 4-Point pharmacophoric fingerprints 
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Considering the internal cross-validation performances, the ligand and target 
prediction models have nearly the same performance, with AUCs of over 0.85 
and MCC ranging from 0.48 to 0.50. With regard to external test set 
predictions, models based on Mold2 and 4-PFPs are more efficient in predicting 
external ligands and targets (Table 10) than Open Babel fingerprint models.  
The low performance of the Open Babel models can be attributed to the 
simplistic functional groups description provided by the Open Babel 
fingerprints. These descriptors are less informative than the more complex 
Mold2 and 4-PFPs, which capture additional information relevant for making 
good predictions. 
 
Predicting the activities of test set kinases using the models based on target 
prediction datasets with AUCs above 0.87 (Table 10) shows that the target 
prediction PCM models can be used to estimate the polypharmacological 
profiles of the kinase inhibitors with reasonable accuracy. 
 
Efforts to compare the classification performances based on different kinase 
families revealed no significant differences in AUCs, except that the AGC and 
OPK families have low sensitivities owing to the sparse distribution of activity 
points and the presence of few closer homologues. Furthermore, analysis of the 
prediction performances of data retrieved from different sources (Ambit, Metz, 
GSK and Millipore) suggested that prediction accuracies are independent of the 
data source and activity type (pKd, inhibition%, residual activity). Prediction 
accuracies are reasonable provided that sufficient data points are available for 
each activity category.  
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5 Visual interpretation of PCM models 
An important aspect of the field-based PCM modelling is the ability to acquire 
visual interpretation of both the protein and ligand features important for 
binding affinity and selectivity, simultaneously. Interpreting the PLS 
continuous models on kinase dataset (Publication I) revealed that the presence 
of polar, lipophilic and unstable water field points in close proximity to the 
well-conserved hinge motifs is generally important for the affinity of ABL1 
kinase towards any ligand (Figure 26 a, b). Likewise, for Dasatinib to interact 
with any kinase, the presence of “hetero-N-nonbasic”, “isothiourea” and 
“hetero-S” functional groups is relevant. To elucidate the features that 
contribute to the selective binding of dasatinib towards ABL1, the protein and 
ligand features should be considered as a combination and not as separate 
entities (Figure 26 c, d). Existence of lipophilic field points near the aryl 
chloride of dasatinib influences selectivity. Further, the unstable water field 
points in this region are expected to promote strong binding, as they are likely 
to be displaced during ligand binding. Additionally, the model suggests that the 
stable water field points near the hydroxy group of dasatinib might influence 
selectivity, probably by mediating the interactions of dasatinib with ABL1 
binding site residues. 
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Figure 26. Protein field points and ligand functional groups relevant for the 
interactions of the inhibitor dasatinib with ABL1 kinase. (a) & (b) Features that 
influence binding affinity. Polar, lipophilic and unstable water field points are shown 
as slate, orange and pink spheres, respectively. (c) & (d) Features related to selectivity. 
Lipophilic, unstable and stable water field points are represented as yellow, red and 
green spheres, respectively. Ligand functional groups (from Open Babel) relevant for 
affinity (N: hetero-N-nonbasic, S: hetero-S, U: isothiourea) and selectivity (Cl: aryl 
chloride, A: primary alcohol) are indicated in blue and magenta, respectively. Figure 
adapted with permission from (Subramanian, V.; Prusis, P.; Pietilä, L. O.; Xhaard, H.; 
Wohlfahrt, G. Visually Interpretable Models of Kinase Selectivity Related Features 
Derived from Field-Based Proteochemometrics. J. Chem. Inf. Model. 2013, 53, 3021–
3030). Copyright (2013) American Chemical Society. 
 
In Publication II, interpretation of the RF classification models provided an 
illustration of the protein and ligand features that make a compound active or 
inactive towards a specific kinase. Features relevant for the interactions of 
TAE-684 towards ALK and AKT2 kinase are presented in Figure 27. Polar and 
unstable water field points near the hinge motif serve as the affinity-promoting 
regions, together with the 4-PFP AAAR. In contrast to the unstable water field 
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points seen in the hydrophobic pocket of ALK kinase, the stable water field 
points in AKT2 kinase are expected to weaken ligand binding, thereby 
contributing to the low affinity of TAE-684 towards AKT2 kinase. Further, the 
interactions between the piperazine moiety of TAE-684 and E1210 in ALK 
kinase is most likely mediated by the stable water present in this region. On the 
other hand, in AKT2 kinase, a phenylalanine (F239) is present in the same 
position as glutamate (E1210) in ALK kinase, which leads to unfavourable 
interactions with piperazine, lowering affinity. 
 
 
 
Figure 27. Protein field points and ligand pharmacophoric groups relevant for the 
strong binding of TAE-684 towards ALK kinase and weak affinity of TAE-684 
towards AKT2 kinase. Polar, lipophilic, unstable and stable water field points that are 
likely to influence affinity are shown as blue, yellow, red and green spheres, 
respectively. 4-PFPs (AARR, AAAR) identified to be important for the interactions of 
TAE-684 and ALK kinase are represented as colored circles (A = H-acceptor (green); 
R = Aromatic ring (brown)). Figure reproduced by permission of The Royal Society of 
Chemistry (Subramanian, V.; Prusis, P.; Xhaard, H.; Wohlfahrt, G. Predictive 
Proteochemometric Models for Kinases Derived from 3D Protein Field-Based 
Descriptors. Med. Chem. Commun. 2016, 7, 1007–1015). 
http://pubs.rsc.org/en/content/articlelanding/2016/md/c5md00556f 
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6 Applicability domain analysis 
Models are considered useful provided that they can be successfully applied to 
predict a new compound or target space. In Publication I, the models had 
limited applicability because the training space includes only active 
representatives of 80 inhibitors and inactives are excluded from the modelling 
domain. Despite these limitations, when applied to a small test set of 25 kinase 
inhibitors, the RMSEPtest obtained was close to 0.8. In Publication II, 64% of 
the test set compounds, whose 4-PFP-based Tanimoto similarities with the 
training set compounds exceeded 0.8, were predicted with more than 80% 
accuracy. Additional efforts to predict external targets revealed that the 
Euclidean distances calculated based on the protein field descriptors should be 
below 0.992 for reliable prediction of test set kinases. In Publication III, 
prediction errors of 84% of the test set compounds were below 1 provided that 
their RDkit-based Tanimoto similarities were above 0.7. Overall, in kinase and 
protease models, a few test set compounds were poorly predicted, despite their 
high similarities with the training set.  
 
In addition to external test set predictions, the applicability domain was further 
explored by LOTO and LOCCO validations. LOTO validations on kinase 
(Publication I) and protease datasets (Publication III) resulted in average 
RMSEPs of 0.820? 0.022 and 1.302??????? respectively. Even though the 
LOTO RMSEPs seem to be higher than the model’s global RMSEPs, assessing 
the predictions of individual targets showed that the models can be extrapolated 
to novel targets provided that there are some close homologues whose activity 
space overlaps with the target to be predicted. In Publication III, LOCCO 
models with excluded compound clusters had a significant drop in performance. 
Further, the high RMSEPs (1.550??????? resulting from LOCCO validations 
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revealed that it is more demanding to extrapolate to novel compound space for 
the serine protease dataset.  
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Additional Unpublished Results 
1 PCM models on superimposed protein fields and Zernike descriptors: a 
comparative study 
As protein fields are sensitive to errors in protein structural alignments, there is 
a need to investigate the extent to which these errors can influence a model’s 
prediction power. PCM models based on protein fields and alignment-
independent Zernike descriptors (N=10) were built using RDkit fingerprints as 
ligand descriptors (Table 11). RF classification and RF regression techniques 
were used to model the bioactivities of kinases and serine proteases, 
respectively.  
 
Table 11. RF-based PCM models on superimposed protein fields and Zernike 
descriptors. 
 
Protein 
descriptors 
Ligand 
descriptors 
Cross-validation 
(MCCa / Q2b) 
External Prediction 
(MCC / R2ctest) 
Kinase dataset (classification) a 
Protein fields 
RDkit 
0.52 0.48 
Zernike (N=10) 0.48 0.48 
Serine protease dataset (Continuous) b 
Protein fields 
RDkit 
0.67 0.71 
Zernike (N=10) 0.67 0.71 
a Matthews correlation coefficient (MCC) values reported for classification models 
b Predictabilities (Q2)  resulting from cross-validation 
c Correlation (R2test) resulting from external test set predictions reported for continuous 
models 
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Comparing the model performances based on protein fields and Zernike 
descriptors, the predictions seem to be nearly the same during both internal 
cross-validation and external predictions (Table 11). Similar trends were 
observed for both kinase and serine protease datasets, suggesting that the 
structural alignments used for field calculations are reasonably good and the 
global performances of the models are not affected. 
 
An in-depth analysis was conducted to examine the prediction differences of 
the individual kinases and serine proteases. When the predictions made by 
field-based and Zernike descriptor-based PCM models for the individual 
observations were compared (Table 12), the correlation of 0.77 for kinases and 
0.92 for serine proteases confirms the robustness of field-based and Zernike 
descriptor models, in terms of predictions, with a few exceptions. On analysis 
of the individual predictions of kinases, predictions based on Zernike 
descriptors were found to improve by at least 10% for five kinases. It is 
probable that these kinases had poor superimposition, which in turn contributed 
to shifts in field positions and hence the predictions were affected in field-based 
models. On the other hand, predictions based on Zernike descriptors 
deteriorated by more than 10% for nearly 15 kinases. This drop in predictions 
could be attributed to the information loss that occurs during the transformation 
of fields to alignment-independent descriptors. A slightly different scenario was 
observed in serine protease models, as the predictions based on Zernike 
descriptors improved by 10% for only one protease and reduced by 10% for 
three proteases. Overall, the protease models are more stable with respect to 
predictions. 
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Nevertheless, the results obtained for Zernike descriptors are preliminary. A 
detailed analysis concerning the shifts in protein structure alignments and 
subsequently field point positions is necessary to draw further conclusions. 
 
Table 12. Comparison of prediction performances of protein fields and Zernike 
descriptor-based (N=10) PCM models.  
 
Protein 
target 
Performance 
measure 
R2(fields,Zernike)a 
Predictions of individual proteins 
Improved by 
atleast 10%d 
Reduced by 10% 
or moree 
Kinases MCCb 0.77 DAPK1, GAK, 
EPHA7, 
CAMKK2, ERK1 
MAPKAPK2, 
GSK3B, DRAK2, 
ALK, EPHA3, 
PAK7, EPHB4, 
PRKR, JNK1, 
CSNK1G3, 
CAMK4, RET, 
MEK1, CSNK1G1, 
EFGR_mut 
Serine 
proteases 
R2testc 0.92 APC FXIIa, KLK5, FIXa 
a Correlation between predictions obtained from field-based and Zernike descriptor- 
based PCM models 
b Matthews correlation coefficient 
c Correlation resulting from external test set predictions 
d Kinases whose MCC values and serine proteases whose R2test values improved by 
atleast 10% 
e Kinases whose MCC values and serine proteases whose R2test values reduced by 10% 
or more 
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2 Impact of expansion order in Zernike descriptor-based PCM modelling 
It is often a challenge to decide the extent to which Zernike polynomials should 
be expanded. Expanding the Zernike polynomials increases the level of 
description and captures more information from the protein fields. As there are 
no standard methods, the order of expansion is decided on a trial and error 
basis. Therefore, the Zernike descriptors were calculated by assigning a series 
of N values (N=3, 5, 10, 20, 30, 40, 50). Performances of PCM models based 
on Zernike descriptors (Table 13) remained nearly the same up to the order of 
40 for both internal and external validations (MCC: 0.46 - 0.50). Expanding the 
Zernike polynomials further by setting N to 50 led to a decrease in both internal 
and external MCCs, suggesting that these descriptors tend to add random noise 
to the models. The model performances neither increase nor decrease 
significantly by expanding Zernike polynomials beyond the order of 10. As 
inclusion of irrelevant descriptors is likely to result in overfitted models, the 
optimal value of N can be chosen as 10.  
 
Table 13. Impact of expansion order in Zernike descriptors based PCM modelling on 
kinase dataset. 
Order of 
expansion (N) 
No. of Zernike 
descriptors 
Cross-validation 
(MCC)a 
External Prediction 
(MCC)a 
3 6 0.49 0.47 
5 12 0.49 0.48 
10 36 0.48 0.48 
20 121 0.50 0.48 
30 256 0.49 0.47 
40 441 0.49 0.46 
50 676 0.47 0.44 
aMatthews correlation coefficient 
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Discussion 
1 Impact of data quality and coverage in PCM modelling 
Information-rich databases like ChEMBL (Bento et al., 2014), BindingDB (Liu 
et al., 2007), PDBbind (Wang et al., 2005) and PubChem (Kim et al., 2016) 
offer the possibility to conduct large-scale data analysis and generate QSAR / 
PCM models to elucidate structure activity relationships of specific targets or 
target families. Nevertheless, the inconsistencies found in these databases 
resulting from multiple measurements by different assays for the same protein-
ligand pair, incorrect structures, erroneous measurement units and incorrect 
values raise concern about the data quality and their use for generating 
empirical models (Williams and Ekins, 2011, Tiikkainen et al., 2012).  
 
The reliability of the models based on experimental data collected from various 
sources and different assay conditions is often questionable. Yet, another 
concern is the reproducibility. Experimental measurements made for a specific 
protein-ligand pair by two different laboratories can have significant variations, 
as reported in Publication I. Lack of standard operating protocols often makes it 
difficult to compare the experimental results. The reproducibility issues can 
impose limitations on model quality and their usefulness for making further 
predictions. Despite these limitations, the wealth of data available in public 
databases is frequently exploited in QSAR and PCM modelling.  
 
Data collection suitable for model generation is a crucial step and it should be 
done with caution. Building models exclusively by utilizing the data from well-
curated sources as in Publication I, can limit the applicability domain of the 
models. Extracting data from various sources after applying certain filters 
(Kramer et al., 2012) and ensuring checks for data quality (Tiikkainen et al., 
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2012) would help to establish predictive modelling. An alternative option 
would be to use manually curated datasets, which has been thoroughly 
investigated in terms of data quality and coverage. Such large datasets are 
frequently not available for many targets. However, the recently published 
proteochemometric models on kinases with 356908 data points (Christmann-
Franck et al., 2016) and the ligand-based activity prediction models generated 
for a set of 280 kinases (Merget et al., 2016) serve as examples of large-scale 
predictive modelling.  
 
Data coverage is yet another important aspect in PCM modelling. It is often 
demanding to generate datasets with a complete bioactivity matrix. In 
Publications II and III, the sparse activity matrix led to a rise in prediction 
errors for a few test set compounds that had good overlap with the training set 
descriptor space. The model’s robustness increases with data coverage, which 
in turn limits the application of proteochemometric approaches for some of the 
less extensively studied targets, with meager activity data. 
 
2 Availability of structures for field-based PCM modelling 
Protein fields used for PCM modelling are highly dependent on X-ray 
structures. It is often challenging to find crystal structures with high resolution 
and completeness for all of the targets included in PCM modelling. Lack of 
crystal structures limits the use of field-based PCM for these targets. This is 
true for GPCRs with only a few solved crystal structures. Using homology 
models for field calculations could be an alternative. However, homology 
models have their own limitations, as the model quality depends on sequence 
identity with the template and correctness of the alignment. Homology models 
are frequently mere reflections of template structures and fail to account for 
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protein flexibility and structurally more different areas, which in turn adds to 
errors during field calculations and subsequent PCM modelling. 
 
3 DFG-in (active) and DFG-out (inactive) conformations of kinases 
As protein fields are influenced by conformational flexibilities of the target 
protein, it is necessary to separate the active and inactive conformations of 
kinases prior to field calculations. It is easy to distinguish between DFG-in and 
DFG-out kinase structures by means of manual inspection, considering the 
orientation of phenylalanine in the DFG motif. However, the experimental data 
lack clear-cut information regarding the binding modes of inhibitors, which 
makes it difficult to discriminate DFG-in and DFG-out inhibitors. PCM models 
in Publications I and II are based on the DFG-in conformations of kinases, 
owing to the presence of abundant structural data for active conformations. The 
selection of DFG-in like inhibitors in Publication I is based on the information 
available in the literature (Karaman et al., 2008; Uitdehaag and Zaman, 2011) 
and a similarity search conducted against the known references. It is probable 
that there are more DFG-out-like inhibitors than the ones described in the 
literature. Combining protein fields generated from DFG-in conformations 
together with the experimental data of DFG-out inhibitors could lead to 
additional sources of error in PCM modelling.  
 
4 Influence of ligand conformations in PCM modelling  
In Publication II, the influence of 3D conformation generation in 4-PFP 
descriptor calculations and subsequent PCM modelling was investigated. The 
results show that neither the 4-PFP calculations nor the model’s overall 
performances are affected by the ligand conformations used. Nevertheless, the 
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probability of predicting active ligands correctly improved by using the lowest 
energy conformation, when compared to the other higher energy conformations. 
 
In Publication III, models based on 3D GRIND descriptors had the worst 
performance, despite using the lowest energy conformation. However, the 4-
PFP models on serine proteases performed better than the GRIND models, 
further confirming that 4-PFPs are less sensitive to the conformations used. In 
case of GRIND models, the starting conformations used for descriptor 
calculations have an impact on the model performance (Caron et al., 2007). 
Therefore, it is not straightforward to generalize that PCM models are not 
influenced by 3D ligand conformations used for descriptor calculations. It 
should rather be considered on a case-by-case basis, depending on the 
descriptor type and the flexibility of the ligands. 
 
5 QSAR versus Field-based PCM 
In Publications I and III, field-based PCM is shown to be clearly advantageous 
over traditional QSAR methods. In Publication I, reliable QSAR models were 
obtained for only 44% of the kinase targets with a wide range of activity values, 
which serves as evidence that ligand descriptors alone cannot capture all of the 
features relevant for binding. Moreover, to understand selectivity with respect 
to different targets, comparison of multiple QSAR models is required, which is 
frequently not feasible considering the data availability for individual targets. 
Even though some targets have limited data, field-based PCM models that take 
advantage of the protein structural information and ligand description of 
multiple targets and ligands allow investigation of the target-ligand interaction 
space in greater depth. However, the field-based PCM models have their own 
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limitations such as issues with data coverage, availability of crystal structures 
and poor protein superimposition affecting field calculations.  
 
6 Predicting mutants in field-based PCM studies 
Previously conducted studies on kinases and proteases have shown that mutants 
can cause drug resistance, thereby revealing the need for the design of 
inhibitors targeting these mutants (Gorre et al., 2001; Kovalevsky et al., 2006). 
Sequence-based PCM studies conducted on HIV protease mutants serve as an 
example for using PCM to predict the bioactivities of mutants (Lapins et al., 
2008; Van Westen et al., 2013). However, the field-based PCM models 
reported in our studies have limitations in predicting the activities of mutant 
types. The limited structural and activity data for mutant structures have 
restricted our studies mostly to wild types. In kinase PCM modelling, EGFR 
mutant T719S was included in the external test set. Prediction accuracy of this 
mutant was quite limited due to the absence of similar mutant representatives in 
the training set. Nevertheless, availability of more structural and activity data 
would support field-based PCM modelling of mutants in the future. 
 
7 Complementarity of docking and field-based PCM approaches 
Docking, a commonly used structure-based approach in drug design to study 
the interactions between proteins and ligands provides 3D illustrations of the 
features that affect binding. Although, docking aims to provide visual 
interpretation as that of field-based PCM, there is a need to conduct several 
docking experiments to estimate selectivity. The problems inherent to docking, 
such as difficulties in generating the right binding pose and poor abilities to 
rank binding affinities, can sum up to large errors in identifying the compounds 
that bind selectively. Nevertheless, docking does not require large-scale 
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experimental data for a set of compounds measured against a panel of targets, 
unlike PCM modelling. Overall, docking and field-based methods complement 
each other, with neither superior to the other. 
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Conclusions and Perspectives 
The current study is dedicated to the development of field-based 
proteochemometrics, tackling limitations in visual interpretability, a frequent 
issue encountered in sequence-based PCM models. In Publication I, PCM 
studies on kinases demonstrated the first successful application of field-based 
PCM to generate visually interpretable models. Possibilities to visually inspect 
the features that affect the selective binding of a drug towards a target are 
highly beneficial in suggesting suitable chemical modifications and designing 
compounds with improved efficacy. Subsequent studies on kinases in 
Publication II proved that the protein field-based descriptors also have the 
potential to generate predictive PCM models. The highlight of this study is the 
estimation of potential polypharmacology, which could be valuable for the 
design of new kinase inhibitors. Further, studies on serine proteases in 
Publication III provided an example that field-based PCM can be applied to any 
target family with well-characterized 3D structures and adequate experimental 
data.  
 
In summary, PCM models can be used to investigate the target-ligand 
interaction space in greater depth, hence being more advantageous than the 
traditional QSAR approaches. Field-based PCM models are either more 
predictive, as in kinases, or as predictive as sequence-based models in serine 
proteases with the benefit of visual interpretation. The ability to illustrate 
molecular interactions similar to structure-based approaches like docking 
together with the possibilities to extrapolate to novel chemical and target space 
makes field-based PCM a promising approach. 
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Field-based PCM studies conducted so far provide clear evidence for the 
usefulness of the method in drug design, and new avenues for further 
development are likely to emerge. The protein fields used for PCM modelling 
are generated from a single protein structure. The different binding modes of 
the ligands, their flexibilities and the conformational changes of the protein 
induced during ligand binding influence the field calculations, and this might 
have an impact on the predictions of novel ligands in PCM modelling. 
Generating fields based on an ensemble of protein conformations could solve 
this problem to some extent. Currently, the model interpretation procedure is 
highly demanding, as it involves extensive manual work. Selectivity 
interpretation is restricted to the top 5 or 10 cross-terms. Automating the field 
interpretations would enable interpretation of all cross-terms, thereby providing 
a more thorough understanding of the selectivity-related features. Also, there is 
a need to investigate PCM modelling based on alignment-independent Zernike 
descriptors in greater depth. Conducting further comprehensive studies by 
introducing artificial shifts in alignments and analysing their effects on field 
calculations and Zernike descriptors could shed light on the prediction issues in 
PCM modelling, probably caused by the fields calculated from misaligned 
structures.  
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